<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">101128</article-id><article-id pub-id-type="doi">10.7554/eLife.101128</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101128.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Hang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-6361-8955</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ji</surname><given-names>Shengwei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7380-4809</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ariefta</surname><given-names>Nanang R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3012-6005</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Galon</surname><given-names>Eloiza May S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2411-8401</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>El-Sayed</surname><given-names>Shimaa AES</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Do</surname><given-names>Thom</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Lijun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sakaguchi</surname><given-names>Miako</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Asada</surname><given-names>Masahito</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0042-6856</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Nishikawa</surname><given-names>Yoshifumi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5005-6377</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Xin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6448-5180</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Mingming</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5935-6736</contrib-id><email>lmm_2010@hotmail.com</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xuan</surname><given-names>Xuenan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2780-110X</contrib-id><email>gen@obihiro.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02t9fsj94</institution-id><institution>National Research Center for Protozoan Diseases, Obihiro University of Agriculture Veterinary Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Obihiro</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/039xnh269</institution-id><institution>Department of Veterinary Medicine, Agriculture College of Yanbian University</institution></institution-wrap><addr-line><named-content content-type="city">Yanji</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043say313</institution-id><institution>College of Veterinary Medicine and Biomedical Sciences, Cavite State University</institution></institution-wrap><addr-line><named-content content-type="city">Indang</named-content></addr-line><country>Philippines</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01k8vtd75</institution-id><institution>Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Mansoura University</institution></institution-wrap><addr-line><named-content content-type="city">Mansoura</named-content></addr-line><country>Egypt</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ppx1p25</institution-id><institution>Central Laboratory, Institute of Tropical Medicine (NEKKEN), Nagasaki University</institution></institution-wrap><addr-line><named-content content-type="city">Nagasaki</named-content></addr-line><country>Japan</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0212jcf64</institution-id><institution>School of Basic Medicine, Hubei University of Arts and Science</institution></institution-wrap><addr-line><named-content content-type="city">Xiangyang</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Research Center for Asian Infectious Diseases, The University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Andayi</surname><given-names>Warren Andrew</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057k4ej49</institution-id><institution>Murang'a University of Technology</institution></institution-wrap><country>Kenya</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01swzsf04</institution-id><institution>University of Geneva</institution></institution-wrap><country>Switzerland</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>06</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP101128</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-07-15"><day>15</day><month>07</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-07-15"><day>15</day><month>07</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.07.15.603500"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-11"><day>11</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101128.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-03-18"><day>18</day><month>03</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101128.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-05-14"><day>14</day><month>05</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101128.3"/></event></pub-history><permissions><copyright-statement>© 2024, Li, Ji et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Li, Ji et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-101128-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-101128-figures-v1.pdf"/><abstract><p>Babesiosis is a disease brought on by intraerythrocytic parasites of the genus <italic>Babesia</italic>. Current chemotherapies are accompanied by side effects and parasite relapse. Therefore, it is crucial to develop highly effective drugs against <italic>Babesia</italic>. Cipargamin (CIP) has shown inhibition against apicomplexan parasites, mainly <italic>Plasmodium</italic> and <italic>Toxoplasma</italic>. This study evaluated the growth-inhibiting properties of CIP against <italic>Babesia</italic> spp. and investigated the mechanism of CIP on <italic>B. gibsoni</italic>. The half inhibitory concentration (IC<sub>50</sub>) values of CIP against the in vitro growth of <italic>B. bovis</italic> and <italic>B. gibsoni</italic> were 20.2 ± 1.4 and 69.4 ± 2.2 nM, respectively. CIP significantly inhibited the growth of <italic>B. microti</italic> and <italic>B. rodhaini</italic> in vivo. Resistance was conferred by L921V and L921I mutations in BgATP4, which reduced the sensitivity to CIP by 6.1- and 12.8-fold. The inhibitory potency of CIP against BgATP4-associated ATPase activity was moderately reduced in mutant strains, with a 1.3- and 2.4-fold decrease in BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup>, respectively, compared to that of BgATP4<sup>WT</sup>. An in silico investigation revealed reductions in affinity for CIP binding to BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup> compared to BgATP4<sup>WT</sup>. Resistant strains showed no significant cross-resistance to atovaquone or tafenoquine succinate (TQ), with less than a onefold change in IC<sub>50</sub> values. Combining CIP with TQ effectively eliminated <italic>B. microti</italic> infection in SCID mice with no relapse, and parasite DNA was not detected by qPCR within 90 days post-infection. Our findings reveal the efficacy of CIP as an antibabesial agent, its limitations as a monotherapy due to resistance development, and the potential of combination therapy with TQ to overcome said resistance and achieve complete parasite clearance.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>Babesia</italic> spp.</kwd><kwd>cipargamin</kwd><kwd>drug resistance</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>22H0250906</award-id><principal-award-recipient><name><surname>Xuan</surname><given-names>Xuenan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003993</institution-id><institution>Ministry of Agriculture, Forestry and Fisheries</institution></institution-wrap></funding-source><award-id>JPJ008837</award-id><principal-award-recipient><name><surname>Xuan</surname><given-names>Xuenan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The potential of repurposing cipargamin for treating <italic>Babesia</italic> species offers both theoretical advancements and practical applications in combating parasitic infections.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>Babesia</italic> is an apicomplexan tick-transmitted hemoparasite, which not only impacts the livestock economy but also causes an emerging disease in humans (<xref ref-type="bibr" rid="bib16">Jalovecka et al., 2019</xref>). <italic>Babesia</italic> is a global pathogen that is more prevalent in certain regions such as Asia, Europe, and North America. However, as climate change brings with it higher temperatures and humidity, ticks and their reservoir hosts are anticipated to expand northward for survival and activity (<xref ref-type="bibr" rid="bib11">Gray and Ogden, 2021</xref>). The disease is known as babesiosis, commonly characterized by fever and hemolytic anemia, but chronic infections can be asymptomatic (<xref ref-type="bibr" rid="bib1">Almazán et al., 2022</xref>). The fatality rate ranges from 1% among all cases to 3% among hospitalized cases, and as high as 20% in immunocompromised patients (<xref ref-type="bibr" rid="bib23">Krause, 2019</xref>).</p><p>Currently, the most common drugs for the treatment of human babesiosis include a combination of atovaquone (ATO) plus azithromycin (AZI) or clindamycin (CLN) plus quinine (QUI) (<xref ref-type="bibr" rid="bib24">Krause et al., 2021</xref>). Still, these recommended treatments often result in various problems. For instance, multiple mutations in the <italic>B. microti</italic> cytochrome b, which is targeted by ATO, were identified in patients with relapsing babesiosis (<xref ref-type="bibr" rid="bib14">Holbrook et al., 2023</xref>; <xref ref-type="bibr" rid="bib25">Krause et al., 2024</xref>; <xref ref-type="bibr" rid="bib29">Lemieux et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Marcos et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Rogers et al., 2023</xref>; <xref ref-type="bibr" rid="bib42">Rosenblatt et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Simon et al., 2017</xref>). The combination of CLN and QUI is the last resort for patients with severe symptoms (<xref ref-type="bibr" rid="bib22">Kletsova et al., 2017</xref>). Despite its efficacy, this combination can elicit adverse drug reactions (<xref ref-type="bibr" rid="bib52">Vannier and Krause, 2012</xref>). The 8-aminoquinoline analog tafenoquine (TQ) was found to be effective in curing immunocompromised patients experiencing relapsing babesiosis caused by <italic>B. microti</italic> (<xref ref-type="bibr" rid="bib41">Rogers et al., 2023</xref>). However, the efficacy of TQ treatment may vary between individuals and cases, and its contraindication in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency limits its clinical use (<xref ref-type="bibr" rid="bib5">Chu and Freedman, 2019</xref>). Due to the aforementioned issues, it is undoubtedly urgent to search for compounds that treat infections caused by <italic>Babesia</italic> spp. while simultaneously minimizing the detrimental side effects of antibabesial drugs.</p><p>Spiroindolone cipargamin (CIP), a promising antimalarial, has been found to effectively suppress the growth of all strains of <italic>Plasmodium falciparum</italic> and <italic>P. vivax</italic> with potency in the low nanomolar ranges (<xref ref-type="bibr" rid="bib43">Rosling et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Rottmann et al., 2010</xref>). The assessment of the drug indicated that CIP taken orally had good absorption, a long half-life, and exceptional bioavailability (<xref ref-type="bibr" rid="bib46">Schmitt et al., 2022</xref>). Following oral CIP treatment (30 mg daily for 3 days) in adults with simple <italic>P. falciparum</italic> or <italic>P. vivax</italic> malaria, parasitemia was rapidly cleared in a phase II trial (<xref ref-type="bibr" rid="bib46">Schmitt et al., 2022</xref>). Currently, a clinical trial is being conducted for the intravenous administration of CIP as a treatment for severe malaria patients (<xref ref-type="bibr" rid="bib6">ClinicalTrials, 2024</xref>). CIP was also evaluated for treating toxoplasmosis as a second-line medicine in cases where there are intolerable toxicity issues or allergies to the currently used treatments. Mice infected with <italic>Toxoplasma gondii</italic> that were treated with CIP on the day of infection and the following day had 90% fewer parasites 5 days post-infection (DPI) (<xref ref-type="bibr" rid="bib56">Zhou et al., 2014</xref>).</p><p><italic>Pf</italic>ATP4, a P-type ATPase in <italic>P. falciparum</italic>, functions as a Na<sup>+</sup>/H<sup>+</sup> transporter critical for maintaining ionic balance (<xref ref-type="bibr" rid="bib48">Spillman et al., 2013</xref>). Mutations in <italic>Pf</italic>ATP4 confer resistance to CIP, which disrupts Na<sup>+</sup> homeostasis, leading to increased cytosolic Na<sup>+</sup> concentration and various physiological changes, such as cytosolic alkalinization and osmotic swelling (<xref ref-type="bibr" rid="bib36">Mohring et al., 2022</xref>). These mutations reduce the Na<sup>+</sup>-dysregulating effects of CIP and the resting Na<sup>+</sup> levels. While <italic>Pf</italic>ATP4 is essential for <italic>P. falciparum</italic> survival, its homolog in <italic>T. gondii</italic> (<italic>Tg</italic>ATP4) is less critical, as <italic>T. gondii</italic> experiences brief, high Na<sup>+</sup> exposure and can survive without <italic>Tg</italic>ATP4 expression (<xref ref-type="bibr" rid="bib28">Lehane et al., 2019</xref>).</p><p>Due to its excellent efficacy against other apicomplexan parasites, including <italic>Plasmodium</italic> spp., and its ability to target parasite ATP4—a conserved protein essential for ion homeostasis in apicomplexan organisms—we hypothesize that CIP could also effectively inhibit <italic>Babesia</italic> spp., a related apicomplexan parasite. Therefore, the objectives of this study were to determine whether CIP could inhibit the growth of <italic>Babesia</italic> spp., namely <italic>B. bovis</italic> and <italic>B. gibsoni</italic> in vitro and <italic>B. microti</italic> and <italic>B. rodhaini</italic> in vivo, and identify the inhibitory mechanisms of CIP on <italic>Babesia</italic> parasites.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Inhibitory efficacy of CIP on <italic>B. bovis</italic> and <italic>B. gibsoni</italic> in vitro</title><p>In vitro efficacy of CIP against <italic>B. bovis</italic> and <italic>B. gibsoni</italic> showed a steep growth inhibition curve with half inhibitory concentration (IC<sub>50</sub>) values of 20.2 ± 1.4 nM (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and 69.4 ± 2.2 nM (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), respectively. The 50% cytotoxic concentration (CC<sub>50</sub>) value of CIP on Madin–Darby canine kidney (MDCK) cells and human foreskin fibroblasts (HFFs) was 38.7 ± 2.0 and 70.8 ± 4.9 μM (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), respectively. Based on these values, the predicted selectivity indices, which reflect the drug’s safety and specificity, were calculated to be greater than 500. Furthermore, at a concentration of 100 μM, CIP exhibited a low erythrocyte hemolysis rate of 0.11 ± 0.03% (data not shown).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cipargamin (CIP) demonstrates potent inhibition on <italic>Babesia</italic> spp.</title><p>(<bold>A</bold>, <bold>B</bold>) Dose-dependent growth curve of CIP on <italic>B. bovis</italic> and <italic>B. gibsoni</italic> in vitro. IC<sub>50</sub>: the half maximal inhibitory concentration. (<bold>C</bold>) Inhibitory effects of CIP and atovaquone (ATO) plus azithromycin (AZI) on the proliferation of <italic>B. microti</italic> in BALB/c mice. (<bold>D</bold>) Hematocrit (HCT) values in mice treated with CIP or ATO plus AZI compared with vehicle-treated mice. (<bold>E</bold>) Inhibitory effects of CIP and ATO plus AZI on the proliferation of <italic>B. rodhaini</italic> in BALB/c mice. (<bold>F</bold>) Survival rates of CIP-treated, ATO plus AZI-treated, and vehicle-treated mice. The treatment time is shown by two-way arrows, and significant differences (p &lt; 0.01) between the drug-treated groups (n = 6) and the vehicle-treated control group (n = 6) are indicated by asterisks. The data from one of three individual experiments are expressed as means ± SD. **p ˂ 0.01.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Cytotoxicity assay of CIP on (<bold>A</bold>) Madin-Darby canine kidney (MDCK) cells and (<bold>B</bold>) human foreskin fibroblast (HFF).</title><p>The MTP-500 microplate reader was utilized to detect the absorbance at 450 nm. Each value represents the mean ± SD of three independent experiments carried out in triplicate. CC<sub>50</sub>: the 50% cytotoxic concentration.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>CIP effect on <italic>B. microti</italic> and <italic>B. rodhaini</italic> infections in vivo</title><p>Concurrently, CIP showed effective inhibition on <italic>B. microti</italic> and <italic>B. rodhaini</italic> in vivo. The parasitemia of <italic>B. microti</italic>-infected BALB/c mice increased dramatically in the vehicle-treated control group and peaked at 10 DPI (38.55 ± 4.32%) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). On the other hand, 7 days of treatment with CIP (20 mg/kg) or ATO plus AZI administered orally resulted in a significantly lower peak parasitemia, 1.06 ± 0.20% and 1.61 ± 0.20%, respectively (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Hematocrit (HCT) variations were tracked every 4 days as an indicator of anemia in <italic>B. microti</italic>-infected mice. The vehicle-treated group showed a drop in HCT levels at 12 and 16 DPI (p &lt; 0.01) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). No significant reduction in HCT levels was observed in the CIP-treated group or the ATO plus AZI-treated group (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). This indicates that the administration of CIP could control <italic>B. microti</italic> infection and prevent anemia from developing in <italic>B. microti</italic>-infected mice.</p><p>BALB/c mice infected with <italic>B. rodhaini</italic> treated with sesame oil or ATO plus AZI showed high parasitemia, 90.73 ± 1.97%, and 86.23 ± 3.06%, respectively (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), and all mice died within 7 DPI (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). CIP treatment in <italic>B. rodhaini</italic>-infected mice precluded the emergence of parasitemia for the following 8 days (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), which led to 66.67% of mice surviving the challenge infection (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). At 12 DPI, parasites had recurred in all CIP-treated <italic>B. rodhaini</italic>-infected mice (10.32 ± 15.51%), which were eventually cleared as indicated by undetectable parasites at 18 DPI (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p></sec><sec id="s2-3"><title>Identification of <italic>B. gibsoni</italic> ATP4 mutation in CIP-resistant strains</title><p>After being exposed to CIP at increasing concentrations up to 10 times the IC<sub>50</sub>, the resistant parasites in two of the culture wells were able to regrow. We sequenced the <italic>B. gibsoni</italic> ATP4 gene from the wild-type and two resistant strains. The wild-type strain has a C at nucleotide 2761, which translates to leucine (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). In one resistant strain, a single-nucleotide variant in BgATP4 with a substitution at position 2761 (from C to G) was found—a nonsynonymous coding change from leucine to valine (L921V) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In another resistant strain, the mutation occurred in the same position. However, the nucleotide substitution was from C to A, and the coding changed from leucine to isoleucine (L921I) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Next-generation sequencing (NGS) revealed that for <italic>Bgatp4</italic><sup>2761C&gt;G</sup>, 99.97% of 7,960 reads were G at nucleotide 2761, and for <italic>Bgatp4</italic><sup>2761C&gt;A</sup>, 99.92% of 7862 reads were A at nucleotide 2761 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup> lines were tested for their susceptibility to CIP and had IC<sub>50</sub> values of 421.0 ± 15.9 and 887.9 ± 62.0 nM, respectively (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). These findings demonstrate a 6.1- and 12.8-fold reduction in CIP sensitivity of the resistant parasite lines BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup>.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mutations in BgATP4 mediate cipargamin (CIP) resistance.</title><p>(<bold>A–C</bold>) Representative sequencing chromatogram of wild-type and resistant parasites from CIP-treated <italic>B. gibsoni</italic>. The resistant parasite genomic DNA is extracted from blood samples after a 60-day treatment. The BgATP4 gene was amplified and sequenced using the DNA. (<bold>D</bold>) Genes of high-frequency sequence variants detected by next-generation sequencing (NGS). (<bold>E</bold>) Dose-dependent growth curve of BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup> in vitro. The data from one of three individual experiments are expressed as means ± SD.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Multiple sequence alignment of ATP4 in different species.</title><p>A yellow square and arrow denote the BgATP4 mutation site discovered in this investigation; purple squares and arrows represent sites linked to <italic>P. falciparum</italic> cipargamin (CIP) resistance, and a gray square and arrow represent sites associated with <italic>T. gondii</italic>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>The effect of CIP on BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup> function</title><p>Microscopic observation of thin blood smears was performed to determine the morphological changes of <italic>B. gibsoni</italic> exposed to CIP. The CIP-treated parasites became swollen after incubation with the drug for 72 hr (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). For both the treatment and control groups, one hundred parasites were measured. The mean size of treated parasites was notably bigger than the parasites in the untreated group (p ˂ 0.0001) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Significant vacuolization was observed in the cytoplasm of parasites in the CIP-treated group, as revealed by transmission electron microscopy (TEM). Despite this, the nuclear membrane structure and parasitic membranes remained intact until the parasites were completely destroyed (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). The addition of the ATP4 inhibitor CIP resulted in a time-dependent increase in the concentrations of [Na<sup>+</sup>]<sub>i</sub> in wild-type <italic>B. gibsoni</italic>, with improved signal-to-noise ratios at the higher drug concentration of 20 nM (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). We observed that the Na<sup>+</sup> concentrations in both BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup> lines were lower when compared with those of the control BgATP4<sup>WT</sup> line after being exposed to 20 nM CIP for 20 min, with a significantly lower Na<sup>+</sup> concentration in BgATP4<sup>L921I</sup> (p = 0.0087) (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). We also demonstrated here that the addition of CIP in wild-type <italic>B. gibsoni</italic> caused an increase in the cytosolic pH (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Specifically, 4 min after the drug was added, the average pH of the 20 nM CIP group reached as high as 7.278, while the 1 nM CIP group reached 7.089 and the untreated group reached 7.062 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). The pH values of the 20 nM CIP group were consistently higher than those of the other two groups, although declining with time (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). In resistant lines, a 20-min exposure to 20 nM CIP caused small changes in the pH values compared to the wild-type line, with the BgATP4<sup>L921I</sup> line (7.048 ± 0.042) having a notably lower pH value (p = 0.0229) (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mechanistic basis for resistance to cipargamin (CIP) conferred by the L921V and L921I mutations in BgATP4.</title><p>(<bold>A</bold>) Untreated and CIP-treated parasite morphology after incubation for 72 hr. Scale bar: 5 µm. (<bold>B</bold>) Sizes of 100 parasites in two groups measured with ImageJ software in panel A. Statistically significant differences between the means of variables determined by <italic>t</italic>-test. ****p ˂ 0.0001. (<bold>C</bold>) Transmission electron microscopy (TEM) of untreated and CIP-treated parasite. N, nucleus; SB, spherical body; V, vacuole. Scale bar: 500 nm. (<bold>D</bold>) [Na<sup>+</sup>]<sub>i</sub> concentrations after the addition of CIP in the BgATP4<sup>WT</sup> line. Representative traces from the experiment that highlight the impact of adding 20 nM CIP (blue), 1 nM CIP (green), or 0 nM CIP (grey) on the concentration [Na<sup>+</sup>]<sub>i</sub> of the BgATP4<sup>WT</sup> line. (<bold>E</bold>) Alkalinization of pH<sub>i</sub> in BgATP4<sup>WT</sup> line upon addition of the ATP4 inhibitor. (<bold>F</bold>) Addition of 20 nM CIP to the wild-type and resistant parasite lines results in different [Na<sup>+</sup>]<sub>i</sub> concentrations. (<bold>G</bold>) Addition of 20 nM CIP to the wild-type and resistant parasite lines results in different pH<sub>i</sub> concentrations. (<bold>H</bold>) Data acquired in the low Na<sup>+</sup> condition (containing only the 2 mM Na<sup>+</sup> introduced upon the addition of 1 mM Na<sub>2</sub>ATP) was subtracted from data obtained in the high Na<sup>+</sup> condition to determine the ATPase activity related to the BgATP4 proteins. (<bold>I</bold>) Dose-dependent BgATP4-associated ATPase activity curve of BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup> in vitro. ATPase activity was determined at pH 7.2 in the presence of 150 mM Na<sup>+</sup> and 1 mM Na<sub>2</sub>ATP. Each value represents the mean ± SD derived from a minimum of three biological replicates. *p ˂ 0.05; **p ˂ 0.01.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Proposed mechanism of inhibition of cipargamin (CIP) on wild-type and mutant parasite-infected erythrocytes.</title><p>CIP disrupts the BgATP4 function of wild-type parasites, which causes a net influx of Na<sup>+</sup> and efflux of H<sup>+</sup> from the parasite. The osmotic load imposed on the influx of Na<sup>+</sup> further brings about parasite swelling and internal alkalinization, which are the main factors in <italic>Babesia</italic> death. Mutations in ATP4 minimize the susceptibility to ATP4 inhibitors by recovering H<sup>+</sup> and Na<sup>+</sup> balance, as indicated by the dotted arrows.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Sensitivity of BgATP4-associated ATPase activity to CIP in BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup></title><p>The BgATP4-associated ATPase activity in erythrocytes infected with BgATP4<sup>WT</sup> (6.31 ± 1.20 nmol Pi/mg protein/min), measured in the presence of 150 mM Na<sup>+</sup>, was higher than those observed in BgATP4<sup>L921V</sup> (5.11 ± 0.50 nmol Pi/mg protein/min) and BgATP4<sup>L921I</sup> (4.58 ± 0.53 nmol Pi/mg protein/min) (p = 0.04) (<xref ref-type="fig" rid="fig3">Figure 3H</xref>).</p><p>We further investigated the concentration-dependent inhibition of BgATP4-associated ATPase activity by CIP in wild-type and mutant parasites. In membranes prepared from <italic>B. gibsoni</italic>, CIP inhibited BgATP4-associated ATPase activity with IC<sub>50</sub> values of 111.4 ± 31.8 nM for BgATP4<sup>WT</sup>, 149.8 ± 21.7 nM for BgATP4<sup>L921V</sup>, and 269.5 ± 29.8 nM for BgATP4<sup>L921I</sup>. The potency of CIP in inhibiting BgATP4-associated ATPase activity was reduced by 1.3- and 2.4-fold in membranes prepared from BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup>, respectively, compared to BgATP4<sup>WT</sup> (<xref ref-type="fig" rid="fig3">Figure 3I</xref>).</p></sec><sec id="s2-6"><title>Multiple sequence alignment of <italic>Babesia</italic> ATP4 and molecular docking</title><p>The whole amino acid sequence of <italic>B. gibsoni</italic> ATP4 (GenBank: KAK1443404.1) shared identity values of 29.75%, 49.40%, 49.67%, 62.21%, and 52.47% with <italic>Homo sapiens</italic> ATP4 (GenBank: NM_000704.3), <italic>P. falciparum</italic> ATP4 (GenBank: PF3D7_1211900), <italic>T. gondii</italic> ATP4 (GenBank: XP_018635122.1), <italic>B. bovis</italic> ATP4 (PiroplasmaDB: BBOV_IV010020), and <italic>B. microti</italic> ATP4 (GenBank: BMR1_03g01005), respectively (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>The pLDDT (predicted Local Distance Difference Test) value of BgATP4<sup>WT</sup> prediction was 80.7 using Colab-fold. Multiple potential binding sites for CIP were revealed by blind docking throughout the whole protein surface (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). CIP binds in close proximity to L921, as demonstrated by focused docking on this area (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The contribution of each residue to the predicted binding affinity in either mutant structure was reduced; the precise values of BgATP4<sup>WT</sup> (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), BgATP4<sup>L921V</sup> (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), and BgATP4<sup>L921I</sup> (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) were −6.43, –6.40, and –6.26 kcal/mol, respectively. The interactions of CIP from each docking simulation are shown in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Binding sites proximal to BgATP4 residue 921 predicted by molecular docking.</title><p>(<bold>A</bold>) The lowest energy poses for cipargamin (CIP) were located in reference to the whole protein structure, docking against the WT (green), L921V (yellow), and L921I (pink) mutant BgATP4. The side chain of L921 is also shown in a red stick at its position. (<bold>B–D</bold>) The zoomed views of the binding locations of CIP.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Binding sites for cipargamin (CIP) found by Gnina search across the entire surface of the protein.</title><p>(<bold>A–C</bold>) The binding space of WT, L921V, and L921I mutants in BgATP4 are labeled in green, yellow, and pink, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Cross-resistance of BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup> mutants to ATO and TQ</title><p>The BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup> lines were tested for their susceptibility to ATO and TQ. The IC<sub>50</sub> values for these lines were 380.1 ± 3.1, 412.9 ± 5.4, and 360.3 ± 7.9 nM, respectively, for ATO (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), and 39.5 ± 0.4, 29.9 ± 1.4, and 39.3 ± 0.3 μM, respectively, for TQ (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The IC<sub>50</sub> values for both ATO and TQ in the resistant strains showed only slight changes compared to the wild-type strain, with less than a onefold difference. This minimal variation suggests that the resistant strain has a mild alteration in susceptibility to ATO and TQ, but not enough to indicate strong resistance or significant cross-resistance.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cross-resistance between ATO and TQ in resistant parasites and combination therapy based on cipargamin (CIP) plus TQ.</title><p>(<bold>A</bold>) Dose-dependent growth curve of BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup> by ATO treatment in vitro. (<bold>B</bold>) Dose-dependent growth curve of BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup> by TQ treatment in vitro. (<bold>C</bold>) Inhibitory effects of CIP plus TQ on the proliferation of <italic>B. microti</italic> in SCID mice (n = 5 per group). Treatment started at 4 DPI: CIP was given at 20  mg/kg once daily for 7 days, TQ was administered as a single 20  mg/kg dose, and the combination group received both treatments (CIP at 20  mg/kg once daily for 7 days plus a single dose of TQ at 20  mg/kg). (<bold>D</bold>) Parasite DNA was detected by qPCR on genomic DNA extracted from blood collected from untreated and treated SCID mice infected with <italic>B. microti</italic> at 90 DPI. A dotted gray line across the graph represents the average cut-off Cq value. Cut-off Cq ≤35 was considered positive, while Cq &gt;35 or no amplification was considered negative. Each value represents the mean ± SD derived from a minimum of five biological replicates. NA indicates no amplification.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101128-fig5-v1.tif"/></fig></sec><sec id="s2-8"><title>Combination treatment of CIP plus TQ in SCID mice with <italic>B. microti</italic> infection</title><p>The parasitemia of <italic>B. microti</italic>-infected SCID mice in the vehicle group increased dramatically, peaking at 10 DPI (77.03 ± 2.45%) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Although the trend showed a subsequent decline, the parasitemia remained around 50% until the mice were euthanized at 90 DPI. Treatment with CIP (20 mg/kg) initially reduced parasitemia to undetectable by 18 DPI. However, a relapse occurred, with parasitemia increasing rapidly and stabilizing at levels comparable to the vehicle group during the subsequent observation period. Notably, no mutations were detected in the relapsed <italic>B. microti</italic> parasites from SCID mice (data not shown). In contrast, parasitemia was completely cleared in the TQ and CIP plus TQ groups by 8 DPI and 6 DPI, respectively, with no parasites observed under the microscope thereafter. qPCR analysis at 90 DPI detected parasite DNA in all groups except the CIP plus TQ group (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The repositioning of antimalarial drugs is critical in developing novel strategies for treating babesiosis. CIP is a novel compound that inhibits <italic>Plasmodium</italic> development by targeting ATP4 and has been extensively tested in Phase 1 and 2 clinical trials (<xref ref-type="bibr" rid="bib39">Qiu et al., 2022</xref>). Since ATP4 is conserved across apicomplexans, including <italic>Babesia</italic> species, our study aimed to repurpose the antimalarial CIP by assessing its efficacy on <italic>Babesia</italic> species (<xref ref-type="bibr" rid="bib28">Lehane et al., 2019</xref>). The IC<sub>50</sub> values of CIP against <italic>B. bovis</italic> and <italic>B. gibsoni</italic> in vitro were lower than the previously reported IC<sub>50</sub> value of TQ (<xref ref-type="bibr" rid="bib4">Carvalho et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Ji et al., 2022b</xref>) and ATO against <italic>B. gibsoni</italic> (<xref ref-type="bibr" rid="bib35">Matsuu et al., 2004</xref>). The present investigation also demonstrated that the inhibitory effects of CIP on <italic>B. microti</italic>-infected BALB/c mice were comparable to that of ATO plus AZI, the combination recommended by the CDC in the United States. CIP was also proven to protect mice from the deadly <italic>B. rodhaini</italic> infection, with a survival rate of up to 67%, as recorded in the current trial. These results suggest that CIP may be a potential chemotherapy candidate for babesiosis.</p><p>In a previous study, the <italic>P. falciparum</italic> Dd2 strain that acquired resistance to CIP carried the G358S mutation in the <italic>Pf</italic>ATP4 protein, a <italic>P. falciparum</italic> P-type Na<sup>+</sup> ATPase (<xref ref-type="bibr" rid="bib39">Qiu et al., 2022</xref>). The vital protein ATP4 is found in the parasite plasma membrane and is specific to the subclass of apicomplexan parasites (<xref ref-type="bibr" rid="bib36">Mohring et al., 2022</xref>). To date, in vitro evolution experiments using CIP have produced at least 18 parasite lines with various <italic>Pf</italic>ATP4 mutations (<xref ref-type="bibr" rid="bib27">Lee and Fidock, 2016</xref>; <xref ref-type="bibr" rid="bib44">Rottmann et al., 2010</xref>). In another study involving <italic>T. gondii</italic>, a cell line that carried the mutation G419S in the <italic>Tg</italic>ATP4 gene was 34 times less susceptible to CIP than that of <italic>Tg</italic>ATP4<sup>WT</sup> (<xref ref-type="bibr" rid="bib39">Qiu et al., 2022</xref>). It follows that there is a significant possibility that resistant <italic>Babesia</italic> parasites will emerge from CIP exposure. In this study, we successfully produced two CIP-resistant strains using six independent selections. The newly discovered L921V and L921I mutations in BgATP4 decreased the CIP sensitivity by 6.1 and 12.8 times, respectively. We provided compelling evidence that natural variety mutations L921V and L921I in BgATP4 significantly affected the protein’s susceptibility to CIP inhibition, albeit the mutational sites were different from those of <italic>P. falciparum</italic> and <italic>T. gondii</italic>. Based on our observation, the growth and generation rates of the mutant strains are comparable to those of the wild-type strain.</p><p>Although ATP4 was initially recognized as a Ca<sup>2+</sup> transporter (<xref ref-type="bibr" rid="bib26">Krishna et al., 2001</xref>), current evidence suggests that ATP4 functions as an ATPase for exporting Na<sup>+</sup> while importing H<sup>+</sup> (<xref ref-type="bibr" rid="bib36">Mohring et al., 2022</xref>), as well as causing a variety of other physiological perturbations including an increase in the volume of parasites and infected erythrocytes due to the osmotic impact of the [Na<sup>+</sup>]<sub>cyt</sub> increase (<xref ref-type="bibr" rid="bib8">Dennis et al., 2018</xref>), a decline in cholesterol. Extrusion from the parasite plasma membrane as a result of the increase in [Na<sup>+</sup>]<sub>cyt</sub> (<xref ref-type="bibr" rid="bib7">Das et al., 2016</xref>), and an intensified rigidity of erythrocytes infected with ring-stage parasites (<xref ref-type="bibr" rid="bib55">Zhang et al., 2016</xref>). In this study, the CIP-exposed wild-type <italic>B. gibsoni</italic> became swollen, which was identical to a prior study on <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="bib8">Dennis et al., 2018</xref>). Interestingly, TEM analysis of parasites incubated with CIP revealed ultrastructural alterations characterized by significant vacuole formation in the cytoplasm, a hallmark of stress or early stages of cell death. These changes were similar to those observed in <italic>B. bovis</italic> treated with clotrimazole and ketoconazole, which ultimately led to growth inhibition or parasite death (<xref ref-type="bibr" rid="bib3">Bork et al., 2003</xref>). Despite the vacuolization, the structural integrity of the nucleus and membranes was maintained, suggesting a gradual process where vacuolization precedes complete destruction of the parasite. One explanation is the swelling of the isolated parasites, which can be ascribed to the osmotic consequences of Na<sup>+</sup> uptake and is contingent upon the presence of Na<sup>+</sup> in the external environment.</p><p>The output of Na<sup>+</sup> and input of H<sup>+</sup> diminished upon CIP-induced inhibition of <italic>Pf</italic>ATP4, and the continued outflow of H<sup>+</sup> via V-type H<sup>+</sup>-ATPase led to an alkalinization that ultimately killed the parasites (<xref ref-type="bibr" rid="bib48">Spillman et al., 2013</xref>). Our capacity to measure a time-dependent increase in the concentration of [Na<sup>+</sup>]<sub>i</sub> and pH value for wild-type <italic>B. gibsoni</italic> facilitated us to gain insight into the basic mechanisms of CIP on BgATP4<sup>WT</sup> function. Furthermore, our results corroborate internal alkalinization as the main factor in <italic>Babesia</italic> death and support our hypothesis that the swollen isolated parasites were produced by Na<sup>+</sup> absorption. To explore further how mutations in BgATP4 are associated with the upregulation of the parasite’s [Na<sup>+</sup>]<sub>i</sub> and [H<sup>+</sup>]<sub>i</sub>, we tested two BgATP4-mutant lines that were chosen previously with BgATP4 inhibitors (BgATP4<sup>L921V</sup> and BgATP4<sup>L921I</sup>). Due to the presence of L921V and L921I mutations in drug-resistant strains of BgATP4, the concentration of Na<sup>+</sup> did not increase as much as it would have in the wild-type strain following the addition of 20 nM CIP for 20 min. As intraerythrocytic alkalinization rises, the same outcome happens. From these results, we deduced how natural mutations in BgATP4 may affect ATP4 inhibitor susceptibility by dysregulating H<sup>+</sup> and Na<sup>+</sup> balance, which helped parasites survive in a relatively high concentration of CIP. An illustration of the putative processes for regulating Na<sup>+</sup> and H<sup>+</sup> in erythrocytes infected with the <italic>Babesia</italic> parasite is presented in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p><p>In a previous study’s isolated membrane assay, CIP was found to be more effective at inhibiting parasite development than <italic>Pf</italic>ATP4-associated ATPase activity, and reduced sensitivity of <italic>Pf</italic>ATP4-associated ATPase activity to the medication was associated with a decrease in parasite susceptibility to CIP (<xref ref-type="bibr" rid="bib43">Rosling et al., 2018</xref>). In our study, the higher resistance to CIP-mediated inhibition of parasite proliferation observed in BgATP4<sup>L921I</sup> compared to BgATP4<sup>L921V</sup> correlated with a higher resistance of BgATP4-associated ATPase activity to the drug. These findings provide additional evidence that the ATPase activity measured in this study corresponds to the activity of the BgATP4 protein.</p><p>According to studies using the <italic>Pf</italic>ATP4 model for molecular docking, the G358S mutation results in a steric clash that lowers CIP’s binding affinity (<xref ref-type="bibr" rid="bib39">Qiu et al., 2022</xref>). The results from the current study were similar to the <italic>Pf</italic>ATP4 model. The molecular docking was constructed using a ColabFold model of wild-type BgATP4, which predicted the binding mode and affinity between ATP4 protein and the ligand to provide a possible mechanistic explanation. It suggested that the L921V mutation caused changes at the atomic level, whereas the L921I mutation created a steric clash that reduced the binding affinity of CIP. The predicted affinity score of the L921I mutation was lower than that of the L921V mutation. Thus, it is possible that CIP had a weaker binding to BgATP4<sup>L921I</sup> than to BgATP4<sup>L921V</sup>. These findings are consistent with the results obtained from measuring the IC<sub>50</sub> of the drug against parasites with the L921V and L921I mutations.</p><p>While CIP shows promise as an antibabesial agent, the emergence of resistance emphasizes the importance of rational drug use and the development of combination therapies. Our results demonstrate that CIP did not exhibit cross-resistance with ATO or TQ, as IC<sub>50</sub> values for ATO and TQ in resistant strains showed minimal changes (&lt;1-fold) compared to the wild-type strain. This observation suggests that CIP could be effectively combined with other antibabesial drugs to reduce the risk of resistance development. Previous studies have also reported that a single dose of TQ may not be sufficient to prevent parasite relapse in immunocompromised hosts, recommending either repeated TQ administration or combination therapy with other antibabesial agents to address this issue (<xref ref-type="bibr" rid="bib37">Mordue and Wormser, 2019</xref>). Supporting this approach, our study demonstrates that the combination of CIP plus TQ effectively cleared <italic>B. microti</italic> infections in SCID mice, with no detectable parasitemia or DNA observed at 90 DPI, indicating complete parasite elimination.</p><p>This preclinical finding underscores the potential of the CIP plus TQ combination as a viable treatment strategy for babesiosis, especially in cases where monotherapy is ineffective. Further studies are needed to fully explore the pharmacokinetics, long-term efficacy, and potential side effects of such combinations in clinical settings, ultimately facilitating optimized therapeutic strategies.</p><p>In summary, our findings provide a comprehensive understanding of CIP’s efficacy, mechanism of resistance, and identifying strategies to enhance its therapeutic potential. The combination of CIP with drugs like TQ offers a promising approach to combat babesiosis and mitigate the development of resistance.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Parasite culture</title><p>The parasites <italic>B. gibsoni</italic> Oita strain and <italic>B. bovis</italic> Texas strain were in vitro cultured in 24-well plates and maintained in an atmosphere of 5% CO<sub>2</sub> and 5% O<sub>2</sub> at 37°C (<xref ref-type="bibr" rid="bib32">Liu et al., 2018</xref>). For the in vivo studies, <italic>B. microti</italic> Peabody mjr strain-(ATCC PRA-99) and <italic>B. rodhaini</italic> Australia strain-infected RBCs (iRBCs), which were collected and diluted with phosphate-buffered saline when the parasitemia levels in the donor mice reached ~20% and 50%, respectively, and were intraperitoneally injected into 6-week-old female BALB/c mice. Each BALB/c mouse was infected with 1.0 × 10<sup>7</sup> <italic>B. microti</italic> or <italic>B. rodhaini</italic> iRBCs for the in vivo trials (<xref ref-type="bibr" rid="bib18">Ji et al., 2022a</xref>).</p></sec><sec id="s4-2"><title>In vitro cytotoxicity of CIP and hemolysis rate in canine erythrocytes</title><p>HFFs and MDCK cells were obtained from the American Type Culture Collection (ATCC, catalog number CRL-2522 and CCL-34). Both cell lines were authenticated using short tandem repeat profiling conducted by ATCC to confirm their genetic identities. Additionally, both HFF and MDCK cells were tested and confirmed the absence of mycoplasma contamination by fluorescent Hoechst staining. Cell lines were maintained at 37°C under an atmosphere of 5% CO<sub>2</sub> and 5% O<sub>2</sub>, and the cytotoxic effect of CIP (MedChem Express, Tokyo, Japan) was assessed using a cell viability assay by CCK-8 (Dojindo, Japan) as described previously (<xref ref-type="bibr" rid="bib30">Li et al., 2023</xref>). The selectivity index is calculated as the ratio between the IC<sub>50</sub> and the CC<sub>50</sub> values.</p><p>Canine erythrocytes were collected from healthy beagle dogs raised in NRCPD and stocked in Vega y Martinez (VYM) phosphate-buffered saline solution at 4°C (<xref ref-type="bibr" rid="bib53">Vega et al., 1985</xref>). A canine erythrocyte hemolysis assay was performed at concentrations of 0.1, 1, 5, 10, 25, 50, and 100 µM as previously described (<xref ref-type="bibr" rid="bib2">Ariefta et al., 2022</xref>).</p></sec><sec id="s4-3"><title>Evaluation of the efficacy of CIP against <italic>Babesia</italic> parasites in vitro</title><p>The efficacy of CIP against <italic>B. gibsoni</italic> and <italic>B. bovis</italic> was determined using a fluorescence assay, as previously described (<xref ref-type="bibr" rid="bib12">Guswanto et al., 2014</xref>). The IC<sub>50</sub> values were determined from the fluorescence values and by non-linear regression analysis (curve fit) in GraphPad Prism 9 (GraphPad Software Inc, USA).</p></sec><sec id="s4-4"><title>Chemotherapeutic effects of CIP against <italic>Babesia</italic> infections in vivo</title><p>CIP was evaluated on <italic>B. microti</italic>- and <italic>B. rodhaini</italic>-infected mice, as previously described (<xref ref-type="bibr" rid="bib38">Ndayisaba et al., 2021</xref>; <xref ref-type="bibr" rid="bib51">Tuvshintulga et al., 2022</xref>). When <italic>B. microti</italic>- and <italic>B. rodhaini</italic>-infected mice had a 1% average parasitemia at 4 and 2 DPI, respectively, the drug treatments were administered and continued for 7 days. Three groups of <italic>B. microti</italic>-infected mice were administered different treatments. The CIP group (<italic>n</italic> = 6) and the ATO plus AZI group (<italic>n</italic> = 6) were orally treated with 20 mg/kg CIP and 20 mg/kg ATO plus 20 mg/kg AZI (Sigma, Tokyo, Japan), respectively. All drugs were prepared in sesame oil. The infected mice of the vehicle group (<italic>n</italic> = 6) orally received 0.2 ml of sesame oil as the control. Eighteen mice infected with <italic>B. rodhaini</italic> were likewise placed into three groups for treatment, and they received the same treatments as the mice infected with <italic>B. microti</italic>. A light microscope (Nikon, Japan) and a hematology analyzer (Celltac α MEK-6450, Nihon Kohden Corporation, Tokyo, Japan) were used to assess the parasitemia and HCT levels every 2 and 4 days, respectively.</p></sec><sec id="s4-5"><title>Selection of CIP-resistant <italic>B. gibsoni</italic> in vitro</title><p>Selections were initiated by exposing six independent flasks, each containing 10 μl (5 × 10<sup>6</sup>) <italic>B. gibsoni</italic> iRBCs mixed with 40 μl (4 × 10<sup>8</sup>) RBCs into a 450-μl culture medium, which contained increasing concentrations of CIP: 5, 10, 20, and 30–694 nM (10 × IC<sub>50</sub>). The medium containing CIP was replaced daily until parasites treated with 10 × IC<sub>50</sub> CIP reached multiplication rates that were approximately comparable to those of the untreated controls (<xref ref-type="bibr" rid="bib15">Hwang et al., 2010</xref>). Then, to evaluate the decreased sensitivity to CIP, IC<sub>50</sub> values of resistant strains were determined by nonlinear regression using the GraphPad Prism software.</p></sec><sec id="s4-6"><title>Detection of <italic>B. gibsoni</italic> ATP4 gene mutations</title><p>The genomic DNA of the mutant parasites was extracted and sequenced (<xref ref-type="bibr" rid="bib18">Ji et al., 2022a</xref>). The primer sets used for sequencing are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The single-nucleotide variants were identified by pairwise alignment to the BgATP4<sup>WT</sup> sequence (GenBank: KAK1443404.1). NGS was performed to detect the ratio of wild-type to mutant parasites by using the Illumina NovaSeq6000 sequencing platform (<xref ref-type="bibr" rid="bib17">Jeon et al., 2021</xref>).</p></sec><sec id="s4-7"><title>Morphological changes in CIP-treated in vitro cultured <italic>B. gibsoni</italic></title><p>A microscopy assay was used to detect the morphological changes of wild-type <italic>B. gibsoni</italic> after exposure to 50 nM CIP for three consecutive days (<xref ref-type="bibr" rid="bib33">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Tayebwa et al., 2018</xref>). At 4 days post-treatment, ImageJ software was used to measure the sizes of 100 randomly selected parasites in the CIP-treated group and the control group on Giemsa-stained blood smears. After treating the parasites as described above, iRBCs were fixed in GA fixation buffer (2% glutaraldehyde in 0.1 M sodium cacodylate buffer containing 1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>), then stored in rinse buffer (0.1 M sodium cacodylate buffer containing 1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>) at 4°C for TEM analysis (<xref ref-type="bibr" rid="bib13">Hidayati et al., 2023</xref>).</p></sec><sec id="s4-8"><title>Parasites [Na<sup>+</sup>]<sub>i</sub> and pH<sub>i</sub> measurements</title><p>For both [Na<sup>+</sup>]<sub>i</sub> and pH<sub>i</sub> measurements, the wild-type and mutant parasites were initially separated from erythrocytes by treatment with saponin (0.05% [wt/vol]) for 5 min (<xref ref-type="bibr" rid="bib45">Saliba and Kirk, 1999</xref>). The Na<sup>+</sup>-sensitive fluorescent dye SBFI (Thermo Fisher Scientific; product S1263) was used to quantify intracellular sodium ([Na<sup>+</sup>]<sub>i</sub>). Saponin-isolated parasites (at 1 × 10<sup>8</sup> parasites/ml) were loaded with SBFI (5 μM; in the presence of 0.02% wt/vol Pluronic F127) for 1 hr at room temperature (RT) (<xref ref-type="bibr" rid="bib48">Spillman et al., 2013</xref>). Thereafter, SBFI-loaded parasites were resuspended in physiological saline (120 mM NaCl, 5 mM KCl, 25 mM HEPES, 20 mM <sc>D</sc>-glucose, and 1 mM MgCl<sub>2</sub> [pH 7.1]) at RT in the presence or absence of CIP. A 96-well microtiter plate was filled with around 200 µl of parasite suspension per well. The dye-loaded cells fluoresced at 515 nm after being stimulated at 340 and 380 nm. Parasites loaded with SBFI were suspended in calibration buffers containing [Na<sup>+</sup>] values ranging from 0 to 140 mM (pH 7.1) to establish calibration curves (<xref ref-type="bibr" rid="bib9">Diarra et al., 2001</xref>).</p><p>The cytosolic pH of wild-type and mutant strains was measured using the pH-sensitive fluorescent dye BCECF [2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein] (Biotium; product 51011). The BCECF was added to saponin-isolated parasites by suspension (1 × 10<sup>8</sup> parasites/ml) and incubated for 20 min at 37°C in RPMI-1640 culture medium (Gibco, USA) (<xref ref-type="bibr" rid="bib45">Saliba and Kirk, 1999</xref>). Thereafter, the parasites loaded with dye were rinsed thrice (12,000 × <italic>g</italic>, 1 min) in RPMI-1640 culture medium, then resuspended in physiological saline (as previously mentioned) with or without various concentrations of CIP. A 96-well microtiter plate was filled with around 200 µl of parasite suspension per well. The dye-loaded cells fluoresced at 520 nm after being stimulated at 440 and 490 nm. A pH calibration was carried out for each experiment (<xref ref-type="bibr" rid="bib36">Mohring et al., 2022</xref>).</p></sec><sec id="s4-9"><title>Measurements of membrane ATPase activity</title><p>Membranes from isolated <italic>B. gibsoni</italic> were prepared by lysing the parasites in ice-cold deionized water containing 7 × Protease Inhibitor Cocktail Tablets (Roche, Germany). The membrane preparation was then washed three times with ice-cold deionized water, with protease inhibitors included in the first two washes (<xref ref-type="bibr" rid="bib39">Qiu et al., 2022</xref>). Protein concentrations in the membrane samples were determined using a Bradford assay. The production of inorganic phosphate (Pi) from ATP hydrolysis was measured using the Malachite Green Phosphate Assay (BioAssay Systems, USA). Membrane preparations were diluted in either a high Na<sup>+</sup> solution (final reaction conditions: 150 mM NaCl, 20 mM KCl, 2 mM MgCl<sub>2</sub>, 50 mM Tris, pH 7.2) or a Na<sup>+</sup>-free solution (final reaction conditions: 150 mM choline chloride, 20 mM KCl, 2 mM MgCl<sub>2</sub>, 50 mM Tris, pH 7.2) to achieve a final protein concentration of 40 μg/ml. CIP was added at the concentrations specified in the respective figure legends. Reactions were conducted according to the manufacturer’s protocol provided with the assay kit.</p></sec><sec id="s4-10"><title>Multiple ATP4 sequence alignment and molecular docking</title><p><italic>B. gibsoni</italic> ATP4 (GenBank: KAK1443404.1), <italic>B. bovis</italic> ATP4 (PiroplasmaDB: BBOV_IV010020), <italic>B. microti</italic> ATP4 (GenBank: BMR1_03g01005), <italic>T. gondii</italic> ATP4 (GenBank: XP_018635122.1), and <italic>H. sapiens</italic> ATP4 (GenBank: NM_000704.3) sequences were obtained by a homology search using <italic>P. falciparum</italic> ATP4 (GenBank: PF3D7_1211900). Sequence alignment was analyzed using MUSCLE in Jalview v2.11.3.2 software and BLAST (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/BLAST/">http://www.ncbi.nlm.nih.gov/BLAST/</ext-link>).</p><p>AlphaFold was used to predict the structure of BgATP4<sup>WT</sup> (<xref ref-type="bibr" rid="bib21">Jumper et al., 2021</xref>). Using the GROMACS 2021 Molecular Dynamics package, the energy minimization was carried out following the model’s generation (<xref ref-type="bibr" rid="bib31">Lindahl and Hess, 2021</xref>). The mutations were produced by using CHARMM-GUI PDB reader (<xref ref-type="bibr" rid="bib20">Jo et al., 2014</xref>). PyMOL (version 2.0 Schrödinger, LLC) was used to confirm the position of the mutation site (center: –20.367, 10.904, 9.435; size: 30 × 30 × 30) (<xref ref-type="bibr" rid="bib50">Trott and Olson, 2010</xref>). The ligand molecules CIP were downloaded from PubChem (CID 44469321; <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/44469321">https://pubchem.ncbi.nlm.nih.gov/compound/44469321</ext-link>). The ligand was used to dock with Gnina (<xref ref-type="bibr" rid="bib10">Eberhardt et al., 2021</xref>). The affinity score and binding pose were chosen only from the highest convolutional neural network score results from docking simulations. The models were visualized using the PyMOL Molecular Graphic System and Discovery Studio.</p></sec><sec id="s4-11"><title>Cross-resistance to TQ and ATO in mutant parasites</title><p>The efficacy of TQ and ATO against BgATP4<sup>WT</sup>, BgATP4<sup>L921V</sup>, and BgATP4<sup>L921I</sup> was evaluated using a fluorescence assay, as described above. The IC<sub>50</sub> values were calculated from the fluorescence values using non-linear regression analysis (curve fitting) in GraphPad Prism 9 (GraphPad Software Inc, USA).</p></sec><sec id="s4-12"><title>Efficacy of CIP plus TQ combination therapy in SCID mice infected with <italic>B. microti</italic></title><p>Twenty 6-week-old female immunocompromised mice (C.B-17/IcrJcl-Prkdcscid strain, CLEA Japan, Inc) were intraperitoneally injected with 1.0 × 10<sup>7</sup> of <italic>B. microti</italic>-infected blood cells (<xref ref-type="bibr" rid="bib51">Tuvshintulga et al., 2022</xref>). When the average parasitemia across all mice reached 1% (at 4 DPI), the drug treatments were initiated. The CIP group (<italic>n</italic> = 5) was orally administered 20 mg/kg CIP for 7 days. The TQ group (<italic>n</italic> = 5) was orally administered a single dose of 20 mg/kg TQ. The CIP plus TQ group (<italic>n</italic> = 5) received the combination treatment, following the dosage and administration methods described above. The vehicle group (<italic>n</italic> = 5) orally received 0.2 ml of sesame oil as the control. Thin blood smears were prepared every other day and examined under a light microscope to determine parasitemia levels.</p></sec><sec id="s4-13"><title>qPCR analysis</title><p>To further verify the presence or absence of <italic>B. microti</italic> DNA in treated SCID mice, real-time quantitative PCR analysis was performed as described previously (<xref ref-type="bibr" rid="bib54">Vydyam et al., 2024</xref>). Briefly, genomic DNA was extracted from blood samples (200 μl) collected at 90 DPI and subjected to qPCR analysis using SYBR Green I, targeting a highly conserved region of <italic>Babesia</italic> mitochondrial genome (mtDNA). Primers used were: Bmic-F 5′-<named-content content-type="sequence">TTGCGATAGTAATAGATTTACTGC</named-content>-3′ and B-lsu-R2 5′-<named-content content-type="sequence">TCTTAACCCAACTCACGTACCA</named-content>-3′ (<xref ref-type="bibr" rid="bib40">Qurollo et al., 2017</xref>). The reaction mixture consisted of: 1× Advanced Universal SYBR Green Super Mix (2×) (1725270; Bio-Rad); 0.5 μM of each primer, and 100 ng of genomic DNA.</p></sec><sec id="s4-14"><title>Detection of <italic>B. microti</italic> ATP4 gene mutations in relapsed infected SCID mice</title><p>The genomic DNA of the mutant parasites was extracted and sequenced (<xref ref-type="bibr" rid="bib18">Ji et al., 2022a</xref>). The primer sets used for sequencing are listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. The single-nucleotide variants were confirmed by pairwise alignment to the <italic>Bm</italic>ATP4<sup>WT</sup> sequence (GenBank: BMR1_03g01005).</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Data analysis, namely one-way ANOVA and two-tailed unpaired <italic>t</italic>-tests, was performed using GraphPad Prism (La Jolla, CA, USA) version 9. A p value of &lt;0.05 was considered a statistically significant result.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Software, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Software, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con4"><p>Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Visualization, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Data curation, Visualization</p></fn><fn fn-type="con" id="con8"><p>Visualization, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con10"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con11"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Formal analysis, Supervision, Validation, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals of Obihiro University of Agriculture and Veterinary Medicine, which was also approved by the Committee on the Ethics of Animal Experiments at the Obihiro University of Agriculture and Veterinary Medicine, Japan (permit numbers: animal experiment, 22-145 and 23-132; DNA experiment, 2207 and 2208; pathogen, 202308 and 202306).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primer sets of <italic>B. gibsoni</italic> ATP4.</title></caption><media xlink:href="elife-101128-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Primer sets of <italic>B. microti</italic> ATP4.</title></caption><media xlink:href="elife-101128-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Interactions of CIP from docking simulations.</title></caption><media xlink:href="elife-101128-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-101128-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data have been deposited in the Dryad Digital Repository and can be accessed via <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.8kprr4z02">https://doi.org/10.5061/dryad.8kprr4z02</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Ariefta</surname><given-names>NR</given-names></name><name><surname>Galon</surname><given-names>EMS</given-names></name></person-group><source>Dryad Digital Repository</source><year iso-8601-date="2025">2025</year><data-title>Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate</data-title><pub-id pub-id-type="doi">10.5061/dryad.8kprr4z02</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by a Grant-in-Aid for Scientific Research (22H0250906), the JSPS Core-to-Core program, both from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and a grant from the Strategic International Collaborative Research Project (JPJ008837) promoted by the Ministry of Agriculture, Forestry, and Fisheries of Japan.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almazán</surname><given-names>C</given-names></name><name><surname>Scimeca</surname><given-names>RC</given-names></name><name><surname>Reichard</surname><given-names>MV</given-names></name><name><surname>Mosqueda</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Babesiosis and theileriosis in North America</article-title><source>Pathogens</source><volume>11</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11020168</pub-id><pub-id pub-id-type="pmid">35215111</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariefta</surname><given-names>NR</given-names></name><name><surname>Pagmadulam</surname><given-names>B</given-names></name><name><surname>Nihei</surname><given-names>C-I</given-names></name><name><surname>Nishikawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sparsomycin exhibits potent antiplasmodial activity in vitro and in vivo</article-title><source>Pharmaceutics</source><volume>14</volume><elocation-id>544</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14030544</pub-id><pub-id pub-id-type="pmid">35335918</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>S</given-names></name><name><surname>Yokoyama</surname><given-names>N</given-names></name><name><surname>Matsuo</surname><given-names>T</given-names></name><name><surname>Claveria</surname><given-names>FG</given-names></name><name><surname>Fujisaki</surname><given-names>K</given-names></name><name><surname>Igarashi</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Clotrimazole, ketoconazole, and clodinafop-propargyl inhibit the in vitro growth of Babesia bigemina and Babesia bovis (Phylum Apicomplexa)</article-title><source>Parasitology</source><volume>127</volume><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1017/s0031182003003895</pub-id><pub-id pub-id-type="pmid">14636017</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>LJM</given-names></name><name><surname>Tuvshintulga</surname><given-names>B</given-names></name><name><surname>Nugraha</surname><given-names>AB</given-names></name><name><surname>Sivakumar</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo</article-title><source>Parasites &amp; Vectors</source><volume>13</volume><elocation-id>362</elocation-id><pub-id pub-id-type="doi">10.1186/s13071-020-04235-7</pub-id><pub-id pub-id-type="pmid">32690081</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CS</given-names></name><name><surname>Freedman</surname><given-names>DO</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tafenoquine and G6PD: a primer for clinicians</article-title><source>Journal of Travel Medicine</source><volume>26</volume><elocation-id>taz023</elocation-id><pub-id pub-id-type="doi">10.1093/jtm/taz023</pub-id><pub-id pub-id-type="pmid">30941413</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="web"><person-group person-group-type="author"><collab>ClinicalTrials</collab></person-group><year iso-8601-date="2024">2024</year><article-title>Bethesda (MD): National Library of Medicine (US). Identifier NCT04675931, To evaluate efficacy, safety, tolerability and PK of intravenous cipargamin in participants with severe <italic>Plasmodium falciparum</italic> malaria</article-title><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT04675931">https://clinicaltrials.gov/study/NCT04675931</ext-link><date-in-citation iso-8601-date="2024-04-09">April 9, 2024</date-in-citation></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Bhatanagar</surname><given-names>S</given-names></name><name><surname>Morrisey</surname><given-names>JM</given-names></name><name><surname>Daly</surname><given-names>TM</given-names></name><name><surname>Burns</surname><given-names>JM</given-names></name><name><surname>Coppens</surname><given-names>I</given-names></name><name><surname>Vaidya</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Na+ influx induced by new antimalarials causes rapid alterations in the cholesterol content and morphology of <italic>Plasmodium falciparum</italic></article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005647</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005647</pub-id><pub-id pub-id-type="pmid">27227970</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>ASM</given-names></name><name><surname>Lehane</surname><given-names>AM</given-names></name><name><surname>Ridgway</surname><given-names>MC</given-names></name><name><surname>Holleran</surname><given-names>JP</given-names></name><name><surname>Kirk</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell swelling induced by the antimalarial KAE609 (Cipargamin) and other PfATP4-associated antimalarials</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>62</volume><elocation-id>e00087-18</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.00087-18</pub-id><pub-id pub-id-type="pmid">29555632</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diarra</surname><given-names>A</given-names></name><name><surname>Sheldon</surname><given-names>C</given-names></name><name><surname>Church</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>In situ calibration and [H+] sensitivity of the fluorescent Na+ indicator SBFI</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>280</volume><fpage>C1623</fpage><lpage>C33</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.2001.280.6.C1623</pub-id><pub-id pub-id-type="pmid">11350758</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhardt</surname><given-names>J</given-names></name><name><surname>Santos-Martins</surname><given-names>D</given-names></name><name><surname>Tillack</surname><given-names>AF</given-names></name><name><surname>Forli</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings</article-title><source>Journal of Chemical Information and Modeling</source><volume>61</volume><fpage>3891</fpage><lpage>3898</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.1c00203</pub-id><pub-id pub-id-type="pmid">34278794</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>JS</given-names></name><name><surname>Ogden</surname><given-names>NH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ticks, human babesiosis and climate change</article-title><source>Pathogens</source><volume>10</volume><elocation-id>1430</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10111430</pub-id><pub-id pub-id-type="pmid">34832586</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guswanto</surname><given-names>A</given-names></name><name><surname>Sivakumar</surname><given-names>T</given-names></name><name><surname>Rizk</surname><given-names>MA</given-names></name><name><surname>Elsayed</surname><given-names>SAE</given-names></name><name><surname>Youssef</surname><given-names>MA</given-names></name><name><surname>ElSaid</surname><given-names>EES</given-names></name><name><surname>Yokoyama</surname><given-names>N</given-names></name><name><surname>Igarashi</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Evaluation of a fluorescence-based method for antibabesial drug screening</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>58</volume><fpage>4713</fpage><lpage>4717</lpage><pub-id pub-id-type="doi">10.1128/AAC.00022-14</pub-id><pub-id pub-id-type="pmid">24914124</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidayati</surname><given-names>AR</given-names></name><name><surname>Ilmi</surname><given-names>H</given-names></name><name><surname>Sakura</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>M</given-names></name><name><surname>Ohmori</surname><given-names>J</given-names></name><name><surname>Hartuti</surname><given-names>ED</given-names></name><name><surname>Tumewu</surname><given-names>L</given-names></name><name><surname>Inaoka</surname><given-names>DK</given-names></name><name><surname>Tanjung</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>E</given-names></name><name><surname>Tokumasu</surname><given-names>F</given-names></name><name><surname>Kita</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Dobashi</surname><given-names>K</given-names></name><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Syafruddin</surname><given-names>D</given-names></name><name><surname>Hafid</surname><given-names>AF</given-names></name><name><surname>Waluyo</surname><given-names>D</given-names></name><name><surname>Widyawaruyanti</surname><given-names>A</given-names></name><collab>Melinda</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Effect of geranylated dihydrochalcone from Artocarpus altilis leaves extract on <italic>Plasmodium falciparum</italic> ultrastructural changes and mitochondrial malate: Quinone oxidoreductase</article-title><source>International Journal for Parasitology. Drugs and Drug Resistance</source><volume>21</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2022.12.001</pub-id><pub-id pub-id-type="pmid">36565667</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holbrook</surname><given-names>NR</given-names></name><name><surname>Klontz</surname><given-names>EH</given-names></name><name><surname>Adams</surname><given-names>GC</given-names></name><name><surname>Schnittman</surname><given-names>SR</given-names></name><name><surname>Issa</surname><given-names>NC</given-names></name><name><surname>Bond</surname><given-names>SA</given-names></name><name><surname>Branda</surname><given-names>JA</given-names></name><name><surname>Lemieux</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title><italic>Babesia microti</italic> variant with multiple resistance mutations detected in an immunocompromised patient receiving atovaquone prophylaxis</article-title><source>Open Forum Infectious Diseases</source><volume>10</volume><elocation-id>ofad097</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofad097</pub-id><pub-id pub-id-type="pmid">36968958</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>SJ</given-names></name><name><surname>Yamasaki</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Wickramasekara Rajapakshage</surname><given-names>BK</given-names></name><name><surname>Ohta</surname><given-names>H</given-names></name><name><surname>Maede</surname><given-names>Y</given-names></name><name><surname>Takiguchi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Development and characterization of a strain of Babesia gibsoni resistant to diminazene aceturate in vitro</article-title><source>The Journal of Veterinary Medical Science</source><volume>72</volume><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1292/jvms.09-0535</pub-id><pub-id pub-id-type="pmid">20160418</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalovecka</surname><given-names>M</given-names></name><name><surname>Sojka</surname><given-names>D</given-names></name><name><surname>Ascencio</surname><given-names>M</given-names></name><name><surname>Schnittger</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Babesia life cycle - when phylogeny meets biology</article-title><source>Trends in Parasitology</source><volume>35</volume><fpage>356</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2019.01.007</pub-id><pub-id pub-id-type="pmid">30733093</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>SA</given-names></name><name><surname>Park</surname><given-names>JL</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Goh</surname><given-names>SH</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comparison between MGI and Illumina sequencing platforms for whole genome sequencing</article-title><source>Genes &amp; Genomics</source><volume>43</volume><fpage>713</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1007/s13258-021-01096-x</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Galon</surname><given-names>EM</given-names></name><name><surname>Rizk</surname><given-names>MA</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Zafar</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xuan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Efficacy of the antimalarial MMV390048 against <italic>Babesia</italic> infection reveals phosphatidylinositol 4-kinase as a druggable target for babesiosis</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>66</volume><elocation-id>e0057422</elocation-id><pub-id pub-id-type="doi">10.1128/aac.00574-22</pub-id><pub-id pub-id-type="pmid">35924942</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Galon</surname><given-names>EM</given-names></name><name><surname>Rizk</surname><given-names>MA</given-names></name><name><surname>Tuvshintulga</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zafar</surname><given-names>I</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><name><surname>Yokoyama</surname><given-names>N</given-names></name><name><surname>Xuan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Inhibitory effect of naphthoquine phosphate on Babesia gibsoni in vitro and Babesia rodhaini in vivo</article-title><source>Parasites &amp; Vectors</source><volume>15</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1186/s13071-021-05127-0</pub-id><pub-id pub-id-type="pmid">34991686</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Islam</surname><given-names>SM</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Rui</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Vanommeslaeghe</surname><given-names>K</given-names></name><name><surname>MacKerell</surname><given-names>AD</given-names></name><name><surname>Roux</surname><given-names>B</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CHARMM-GUI PDB manipulator for advanced modeling and simulations of proteins containing nonstandard residues</article-title><source>Advances in Protein Chemistry and Structural Biology</source><volume>96</volume><fpage>235</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/bs.apcsb.2014.06.002</pub-id><pub-id pub-id-type="pmid">25443960</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kletsova</surname><given-names>EA</given-names></name><name><surname>Spitzer</surname><given-names>ED</given-names></name><name><surname>Fries</surname><given-names>BC</given-names></name><name><surname>Marcos</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone</article-title><source>Annals of Clinical Microbiology and Antimicrobials</source><volume>16</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/s12941-017-0198-9</pub-id><pub-id pub-id-type="pmid">28399851</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human babesiosis</article-title><source>International Journal for Parasitology</source><volume>49</volume><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2018.11.007</pub-id><pub-id pub-id-type="pmid">30690090</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>PJ</given-names></name><name><surname>Auwaerter</surname><given-names>PG</given-names></name><name><surname>Bannuru</surname><given-names>RR</given-names></name><name><surname>Branda</surname><given-names>JA</given-names></name><name><surname>Falck-Ytter</surname><given-names>YT</given-names></name><name><surname>Lantos</surname><given-names>PM</given-names></name><name><surname>Lavergne</surname><given-names>V</given-names></name><name><surname>Meissner</surname><given-names>HC</given-names></name><name><surname>Osani</surname><given-names>MC</given-names></name><name><surname>Rips</surname><given-names>JG</given-names></name><name><surname>Sood</surname><given-names>SK</given-names></name><name><surname>Vannier</surname><given-names>E</given-names></name><name><surname>Vaysbrot</surname><given-names>EE</given-names></name><name><surname>Wormser</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis</article-title><source>Clinical Infectious Diseases</source><volume>72</volume><fpage>e49</fpage><lpage>e64</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1216</pub-id><pub-id pub-id-type="pmid">33252652</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>PJ</given-names></name><name><surname>Rogers</surname><given-names>R</given-names></name><name><surname>Shah</surname><given-names>MK</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Parsonnet</surname><given-names>J</given-names></name><name><surname>Kodama</surname><given-names>R</given-names></name><name><surname>Vannier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Tafenoquine for relapsing babesiosis: a case series</article-title><source>Clinical Infectious Diseases</source><volume>79</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1093/cid/ciae238</pub-id><pub-id pub-id-type="pmid">38814096</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishna</surname><given-names>S</given-names></name><name><surname>Woodrow</surname><given-names>C</given-names></name><name><surname>Webb</surname><given-names>R</given-names></name><name><surname>Penny</surname><given-names>J</given-names></name><name><surname>Takeyasu</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>East</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Expression and functional characterization of a <italic>Plasmodium falciparum</italic> Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>10782</fpage><lpage>10787</lpage><pub-id pub-id-type="doi">10.1074/jbc.M010554200</pub-id><pub-id pub-id-type="pmid">11145964</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AH</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Evidence of a mild mutator phenotype in cambodian <italic>Plasmodium falciparum</italic> malaria parasites</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0154166</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0154166</pub-id><pub-id pub-id-type="pmid">27100094</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehane</surname><given-names>AM</given-names></name><name><surname>Dennis</surname><given-names>ASM</given-names></name><name><surname>Bray</surname><given-names>KO</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Rajendran</surname><given-names>E</given-names></name><name><surname>McCoy</surname><given-names>JM</given-names></name><name><surname>McArthur</surname><given-names>HM</given-names></name><name><surname>Winterberg</surname><given-names>M</given-names></name><name><surname>Rahimi</surname><given-names>F</given-names></name><name><surname>Tonkin</surname><given-names>CJ</given-names></name><name><surname>Kirk</surname><given-names>K</given-names></name><name><surname>van Dooren</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Characterization of the ATP4 ion pump in <italic>Toxoplasma gondii</italic></article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>5720</fpage><lpage>5734</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.006706</pub-id><pub-id pub-id-type="pmid">30723156</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemieux</surname><given-names>JE</given-names></name><name><surname>Tran</surname><given-names>AD</given-names></name><name><surname>Freimark</surname><given-names>L</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Goethert</surname><given-names>H</given-names></name><name><surname>Andersen</surname><given-names>KG</given-names></name><name><surname>Bazner</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>McGrath</surname><given-names>G</given-names></name><name><surname>Sloan</surname><given-names>L</given-names></name><name><surname>Vannier</surname><given-names>E</given-names></name><name><surname>Milner</surname><given-names>D</given-names></name><name><surname>Pritt</surname><given-names>B</given-names></name><name><surname>Rosenberg</surname><given-names>E</given-names></name><name><surname>Telford</surname><given-names>S</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Sabeti</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse</article-title><source>Nature Microbiology</source><volume>1</volume><elocation-id>16079</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.79</pub-id><pub-id pub-id-type="pmid">27572973</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Galon</surname><given-names>EM</given-names></name><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Zafar</surname><given-names>I</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Do</surname><given-names>T</given-names></name><name><surname>Amer</surname><given-names>MM</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xuan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>In vitro screening of compounds from the Food and Drug Administration-approved library identifies anti-Babesia gibsoni activity of idarubicin hydrochloride and vorinostat</article-title><source>Parasitology International</source><volume>96</volume><elocation-id>102774</elocation-id><pub-id pub-id-type="doi">10.1016/j.parint.2023.102774</pub-id><pub-id pub-id-type="pmid">37380124</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>A</given-names></name><name><surname>Hess</surname><given-names>SVD</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>GROMACS 2021 manual</data-title><version designator="Version 2021">Version 2021</version><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.4457591">https://doi.org/10.5281/zenodo.4457591</ext-link></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Adjou Moumouni</surname><given-names>PF</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Vudriko</surname><given-names>P</given-names></name><name><surname>Efstratiou</surname><given-names>A</given-names></name><name><surname>Ringo</surname><given-names>AE</given-names></name><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Hakimi</surname><given-names>H</given-names></name><name><surname>Masatani</surname><given-names>T</given-names></name><name><surname>Sunaga</surname><given-names>F</given-names></name><name><surname>Kawazu</surname><given-names>S-I</given-names></name><name><surname>Yamagishi</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Xuan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification and characterization of interchangeable cross-species functional promoters between Babesia gibsoni and Babesia bovis</article-title><source>Ticks and Tick-Borne Diseases</source><volume>9</volume><fpage>330</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.ttbdis.2017.11.008</pub-id><pub-id pub-id-type="pmid">29174364</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Kondoh</surname><given-names>D</given-names></name><name><surname>Galon</surname><given-names>EM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tomihari</surname><given-names>M</given-names></name><name><surname>Yanagawa</surname><given-names>M</given-names></name><name><surname>Tagawa</surname><given-names>M</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Igarashi</surname><given-names>I</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><name><surname>Xuan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tafenoquine is a promising drug candidate for the treatment of babesiosis</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>65</volume><elocation-id>e0020421</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.00204-21</pub-id><pub-id pub-id-type="pmid">33941516</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos</surname><given-names>LA</given-names></name><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Kirkman</surname><given-names>L</given-names></name><name><surname>Wormser</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone</article-title><source>IDCases</source><volume>27</volume><elocation-id>e01460</elocation-id><pub-id pub-id-type="doi">10.1016/j.idcr.2022.e01460</pub-id><pub-id pub-id-type="pmid">35242564</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuu</surname><given-names>A</given-names></name><name><surname>Koshida</surname><given-names>Y</given-names></name><name><surname>Kawahara</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Ikadai</surname><given-names>H</given-names></name><name><surname>Hikasa</surname><given-names>Y</given-names></name><name><surname>Okano</surname><given-names>S</given-names></name><name><surname>Higuchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Efficacy of atovaquone against Babesia gibsoni in vivo and in vitro</article-title><source>Veterinary Parasitology</source><volume>124</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2004.07.005</pub-id><pub-id pub-id-type="pmid">15350657</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohring</surname><given-names>F</given-names></name><name><surname>van Schalkwyk</surname><given-names>DA</given-names></name><name><surname>Henrici</surname><given-names>RC</given-names></name><name><surname>Blasco</surname><given-names>B</given-names></name><name><surname>Leroy</surname><given-names>D</given-names></name><name><surname>Sutherland</surname><given-names>CJ</given-names></name><name><surname>Moon</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cation ATPase (ATP4) orthologue replacement in the malaria parasite <italic>Plasmodium knowlesi</italic> reveals species-specific responses to ATP4-targeting drugs</article-title><source>mBio</source><volume>13</volume><elocation-id>e0117822</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.01178-22</pub-id><pub-id pub-id-type="pmid">36190127</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mordue</surname><given-names>DG</given-names></name><name><surname>Wormser</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Could the drug tafenoquine revolutionize treatment of Babesia microti Infection?</article-title><source>The Journal of Infectious Diseases</source><volume>220</volume><fpage>442</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz119</pub-id><pub-id pub-id-type="pmid">31099380</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ndayisaba</surname><given-names>G</given-names></name><name><surname>Yeka</surname><given-names>A</given-names></name><name><surname>Asante</surname><given-names>KP</given-names></name><name><surname>Grobusch</surname><given-names>MP</given-names></name><name><surname>Karita</surname><given-names>E</given-names></name><name><surname>Mugerwa</surname><given-names>H</given-names></name><name><surname>Asiimwe</surname><given-names>S</given-names></name><name><surname>Oduro</surname><given-names>A</given-names></name><name><surname>Fofana</surname><given-names>B</given-names></name><name><surname>Doumbia</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>JP</given-names></name><name><surname>Barsainya</surname><given-names>S</given-names></name><name><surname>Kullak-Ublick</surname><given-names>GA</given-names></name><name><surname>Su</surname><given-names>G</given-names></name><name><surname>Schmitt</surname><given-names>EK</given-names></name><name><surname>Csermak</surname><given-names>K</given-names></name><name><surname>Gandhi</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with <italic>Plasmodium falciparum</italic> malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa</article-title><source>Malaria Journal</source><volume>20</volume><elocation-id>478</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-021-04009-1</pub-id><pub-id pub-id-type="pmid">34930267</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>D</given-names></name><name><surname>Pei</surname><given-names>JV</given-names></name><name><surname>Rosling</surname><given-names>JEO</given-names></name><name><surname>Thathy</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Tanner</surname><given-names>JD</given-names></name><name><surname>Penington</surname><given-names>JS</given-names></name><name><surname>Aw</surname><given-names>YTV</given-names></name><name><surname>Aw</surname><given-names>JYH</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Tripathi</surname><given-names>AK</given-names></name><name><surname>Gnadig</surname><given-names>NF</given-names></name><name><surname>Yeo</surname><given-names>T</given-names></name><name><surname>Fairhurst</surname><given-names>KJ</given-names></name><name><surname>Stokes</surname><given-names>BH</given-names></name><name><surname>Murithi</surname><given-names>JM</given-names></name><name><surname>Kümpornsin</surname><given-names>K</given-names></name><name><surname>Hasemer</surname><given-names>H</given-names></name><name><surname>Dennis</surname><given-names>ASM</given-names></name><name><surname>Ridgway</surname><given-names>MC</given-names></name><name><surname>Schmitt</surname><given-names>EK</given-names></name><name><surname>Straimer</surname><given-names>J</given-names></name><name><surname>Papenfuss</surname><given-names>AT</given-names></name><name><surname>Lee</surname><given-names>MCS</given-names></name><name><surname>Corry</surname><given-names>B</given-names></name><name><surname>Sinnis</surname><given-names>P</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>van Dooren</surname><given-names>GG</given-names></name><name><surname>Kirk</surname><given-names>K</given-names></name><name><surname>Lehane</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A G358S mutation in the <italic>Plasmodium falciparum</italic> Na<sup>+</sup> pump PfATP4 confers clinically-relevant resistance to cipargamin</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5746</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33403-9</pub-id><pub-id pub-id-type="pmid">36180431</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qurollo</surname><given-names>BA</given-names></name><name><surname>Archer</surname><given-names>NR</given-names></name><name><surname>Schreeg</surname><given-names>ME</given-names></name><name><surname>Marr</surname><given-names>HS</given-names></name><name><surname>Birkenheuer</surname><given-names>AJ</given-names></name><name><surname>Haney</surname><given-names>KN</given-names></name><name><surname>Thomas</surname><given-names>BS</given-names></name><name><surname>Breitschwerdt</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improved molecular detection of Babesia infections in animals using a novel quantitative real-time PCR diagnostic assay targeting mitochondrial DNA</article-title><source>Parasites &amp; Vectors</source><volume>10</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.1186/s13071-017-2064-1</pub-id><pub-id pub-id-type="pmid">28264705</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>R</given-names></name><name><surname>Krause</surname><given-names>PJ</given-names></name><name><surname>Norris</surname><given-names>AM</given-names></name><name><surname>Ting</surname><given-names>MH</given-names></name><name><surname>Nagami</surname><given-names>EH</given-names></name><name><surname>Cilley</surname><given-names>B</given-names></name><name><surname>Vannier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Broad Antimicrobial resistance in a case of relapsing babesiosis successfully treated with tafenoquine</article-title><source>Clinical Infectious Diseases</source><volume>76</volume><fpage>741</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac473</pub-id><pub-id pub-id-type="pmid">35684960</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblatt</surname><given-names>J</given-names></name><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Baneman</surname><given-names>E</given-names></name><name><surname>Fuller</surname><given-names>R</given-names></name><name><surname>Taimur</surname><given-names>S</given-names></name><name><surname>Paniz-Mondolfi</surname><given-names>AE</given-names></name><name><surname>Malone</surname><given-names>AK</given-names></name><name><surname>Kirkman</surname><given-names>L</given-names></name><name><surname>Jacobs</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Relapsed <italic>Babesia microti</italic> Infection following allogeneic hematopoietic cell transplantation in a patient with B-cell acute lymphoblastic leukemia: case report and review of the literature</article-title><source>Open Forum Infectious Diseases</source><volume>8</volume><elocation-id>ofab323</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofab323</pub-id><pub-id pub-id-type="pmid">34514015</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosling</surname><given-names>JEO</given-names></name><name><surname>Ridgway</surname><given-names>MC</given-names></name><name><surname>Summers</surname><given-names>RL</given-names></name><name><surname>Kirk</surname><given-names>K</given-names></name><name><surname>Lehane</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Biochemical characterization and chemical inhibition of PfATP4-associated Na<sup>+</sup>-ATPase activity in <italic>Plasmodium falciparum</italic> membranes</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>13327</fpage><lpage>13337</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.003640</pub-id><pub-id pub-id-type="pmid">29986883</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottmann</surname><given-names>M</given-names></name><name><surname>McNamara</surname><given-names>C</given-names></name><name><surname>Yeung</surname><given-names>BKS</given-names></name><name><surname>Lee</surname><given-names>MCS</given-names></name><name><surname>Zou</surname><given-names>B</given-names></name><name><surname>Russell</surname><given-names>B</given-names></name><name><surname>Seitz</surname><given-names>P</given-names></name><name><surname>Plouffe</surname><given-names>DM</given-names></name><name><surname>Dharia</surname><given-names>NV</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>SB</given-names></name><name><surname>Spencer</surname><given-names>KR</given-names></name><name><surname>González-Páez</surname><given-names>GE</given-names></name><name><surname>Lakshminarayana</surname><given-names>SB</given-names></name><name><surname>Goh</surname><given-names>A</given-names></name><name><surname>Suwanarusk</surname><given-names>R</given-names></name><name><surname>Jegla</surname><given-names>T</given-names></name><name><surname>Schmitt</surname><given-names>EK</given-names></name><name><surname>Beck</surname><given-names>H-P</given-names></name><name><surname>Brun</surname><given-names>R</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Renia</surname><given-names>L</given-names></name><name><surname>Dartois</surname><given-names>V</given-names></name><name><surname>Keller</surname><given-names>TH</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Diagana</surname><given-names>TT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Spiroindolones, a potent compound class for the treatment of malaria</article-title><source>Science</source><volume>329</volume><fpage>1175</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1126/science.1193225</pub-id><pub-id pub-id-type="pmid">20813948</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saliba</surname><given-names>KJ</given-names></name><name><surname>Kirk</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>pH regulation in the intracellular malaria parasite, <italic>Plasmodium falciparum</italic></article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>33213</fpage><lpage>33219</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.47.33213</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>EK</given-names></name><name><surname>Ndayisaba</surname><given-names>G</given-names></name><name><surname>Yeka</surname><given-names>A</given-names></name><name><surname>Asante</surname><given-names>KP</given-names></name><name><surname>Grobusch</surname><given-names>MP</given-names></name><name><surname>Karita</surname><given-names>E</given-names></name><name><surname>Mugerwa</surname><given-names>H</given-names></name><name><surname>Asiimwe</surname><given-names>S</given-names></name><name><surname>Oduro</surname><given-names>A</given-names></name><name><surname>Fofana</surname><given-names>B</given-names></name><name><surname>Doumbia</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>G</given-names></name><name><surname>Csermak Renner</surname><given-names>K</given-names></name><name><surname>Venishetty</surname><given-names>VK</given-names></name><name><surname>Sayyed</surname><given-names>S</given-names></name><name><surname>Straimer</surname><given-names>J</given-names></name><name><surname>Demin</surname><given-names>I</given-names></name><name><surname>Barsainya</surname><given-names>S</given-names></name><name><surname>Boulton</surname><given-names>C</given-names></name><name><surname>Gandhi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Efficacy of cipargamin (KAE609) in a randomized, phase II Dose-escalation study in adults in sub-saharan africa with uncomplicated <italic>Plasmodium falciparum</italic> Malaria</article-title><source>Clinical Infectious Diseases</source><volume>74</volume><fpage>1831</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab716</pub-id><pub-id pub-id-type="pmid">34410358</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>MS</given-names></name><name><surname>Westblade</surname><given-names>LF</given-names></name><name><surname>Dziedziech</surname><given-names>A</given-names></name><name><surname>Visone</surname><given-names>JE</given-names></name><name><surname>Furman</surname><given-names>RR</given-names></name><name><surname>Jenkins</surname><given-names>SG</given-names></name><name><surname>Schuetz</surname><given-names>AN</given-names></name><name><surname>Kirkman</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed babesia microti infection associated with rituximab and chronic lymphocytic leukemia</article-title><source>Clinical Infectious Diseases</source><volume>65</volume><fpage>1222</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1093/cid/cix477</pub-id><pub-id pub-id-type="pmid">28541469</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillman</surname><given-names>NJ</given-names></name><name><surname>Allen</surname><given-names>RJW</given-names></name><name><surname>McNamara</surname><given-names>CW</given-names></name><name><surname>Yeung</surname><given-names>BKS</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Diagana</surname><given-names>TT</given-names></name><name><surname>Kirk</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Na(+) regulation in the malaria parasite <italic>Plasmodium falciparum</italic> involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials</article-title><source>Cell Host &amp; Microbe</source><volume>13</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.12.006</pub-id><pub-id pub-id-type="pmid">23414762</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tayebwa</surname><given-names>DS</given-names></name><name><surname>Tuvshintulga</surname><given-names>B</given-names></name><name><surname>Guswanto</surname><given-names>A</given-names></name><name><surname>Nugraha</surname><given-names>AB</given-names></name><name><surname>Batiha</surname><given-names>GES</given-names></name><name><surname>Gantuya</surname><given-names>S</given-names></name><name><surname>Rizk</surname><given-names>MA</given-names></name><name><surname>Vudriko</surname><given-names>P</given-names></name><name><surname>Sivakumar</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>N</given-names></name><name><surname>Igarashi</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effects of nitidine chloride and camptothecin on the growth of Babesia and Theileria parasites</article-title><source>Ticks and Tick-Borne Diseases</source><volume>9</volume><fpage>1192</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1016/j.ttbdis.2018.04.019</pub-id><pub-id pub-id-type="pmid">29730263</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>Journal of Computational Chemistry</source><volume>31</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuvshintulga</surname><given-names>B</given-names></name><name><surname>Sivakumar</surname><given-names>T</given-names></name><name><surname>Nugraha</surname><given-names>AB</given-names></name><name><surname>Ahedor</surname><given-names>B</given-names></name><name><surname>Batmagnai</surname><given-names>E</given-names></name><name><surname>Otgonsuren</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xuan</surname><given-names>X</given-names></name><name><surname>Igarashi</surname><given-names>I</given-names></name><name><surname>Yokoyama</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Combination of clofazimine and atovaquone as a potent therapeutic regimen for the radical cure of babesia microti infection in immunocompromised Hosts</article-title><source>The Journal of Infectious Diseases</source><volume>225</volume><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab537</pub-id><pub-id pub-id-type="pmid">34664651</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannier</surname><given-names>E</given-names></name><name><surname>Krause</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human babesiosis</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>2397</fpage><lpage>2407</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1202018</pub-id><pub-id pub-id-type="pmid">22716978</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vega</surname><given-names>CA</given-names></name><name><surname>Buening</surname><given-names>GM</given-names></name><name><surname>Green</surname><given-names>TJ</given-names></name><name><surname>Carson</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>In vitro cultivation of Babesia bigemina</article-title><source>American Journal of Veterinary Research</source><volume>46</volume><fpage>416</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">3888009</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vydyam</surname><given-names>P</given-names></name><name><surname>Pal</surname><given-names>AC</given-names></name><name><surname>Renard</surname><given-names>I</given-names></name><name><surname>Chand</surname><given-names>M</given-names></name><name><surname>Kumari</surname><given-names>V</given-names></name><name><surname>Gennaro</surname><given-names>JC</given-names></name><name><surname>Mamoun</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Tafenoquine-atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human Babesiosis</article-title><source>The Journal of Infectious Diseases</source><volume>229</volume><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiad315</pub-id><pub-id pub-id-type="pmid">38169301</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Suwanarusk</surname><given-names>R</given-names></name><name><surname>Malleret</surname><given-names>B</given-names></name><name><surname>Cooke</surname><given-names>BM</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Lau</surname><given-names>YL</given-names></name><name><surname>Dao</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>CT</given-names></name><name><surname>Renia</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>KSW</given-names></name><name><surname>Russell</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609</article-title><source>The Journal of Infectious Diseases</source><volume>213</volume><fpage>100</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv358</pub-id><pub-id pub-id-type="pmid">26136472</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Fomovska</surname><given-names>A</given-names></name><name><surname>Muench</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>BS</given-names></name><name><surname>Mui</surname><given-names>E</given-names></name><name><surname>McLeod</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of <italic>Toxoplasma gondii</italic> tachyzoites in vitro and in vivo</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>58</volume><fpage>1789</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1128/AAC.02225-13</pub-id><pub-id pub-id-type="pmid">24366743</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101128.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Andayi</surname><given-names>Warren Andrew</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Murang'a University of Technology</institution><country>Kenya</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study presents <bold>valuable</bold> findings with practical and theoretical implications for drug discovery, particularly in the context of repurposing cipargamin CIP for the treatment of Babesia spp. The evidence is <bold>solid</bold> with the methods, data, and analyses broadly supporting the claims. The paper will be of great interest to scientists in drug discovery, computational biology, and microbiology.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101128.4.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this manuscript, the authors present the repurposing of cipargamin (CIP), a known drug against plasmodium and toxoplasma against babesia. They proved the efficacy of CIP on babesia in the nanomolar range. In silico analyses revealed the drug resistance mechanism through a single amino acid mutation at amino acid position 921 on the ATP4 gene of babesia. Overall, the conclusions drawn by the authors are well justified by the data presented. I believe this study opens up a novel therapeutic strategy against babesiosis.</p><p>Strengths:</p><p>The authors have carried out a comprehensive study. All the experiments performed were carried out methodically and logically.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101128.4.sa2</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors aim to establish that cipargamin can be used for the treatment of infection caused by Babesia organisms.</p><p>Strengths:</p><p>The study provides strong evidence that cipargamin is effective against various Babesia species. In vitro growth assays were used to establish that cipargamin is effective against Babesia bovis and Babesia gibsoni. Infection of mice with Babesia microti demonstrated that cipargamin is as effective as the combination of atovaquone plus azithromycin. Cipargamin protected mice from lethal infection with Babesia rodhaini. Mutations that confer resistance to cipargamin were identified in the gene encoding ATP4, a P-type Na ATPase that is found in other apicomplexan parasites, thereby validating ATP4 as the target of cipargamin. A 7-day treatment of cipagarmin, when combined with a single dose of tafenoquine, was sufficient to eradicate Babesia microti in a mouse model of severe babesiosis caused by a lack of adaptive immunity.</p><p>Weaknesses:</p><p>Cipargamin was tested in vivo at a single dose administered daily for 7 days. Despite the prospect of using cipargamin for the treatment of human babesiosis, there was no attempt to identify the lowest dose of cipagarmin that protects mice from Babesia microti infection.</p><p>Comments on revisions:</p><p>The authors have edited the manuscript and, in doing so, have addressed all queries pertaining to experimental design. The authors have decided to keep the discussion unchanged, but have replied to this reviewer regarding comments on interpretation of some data. The reader could have benefited from the authors' explanation. Nonetheless, the manuscript in its present form describes a valuable and significant body of work.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101128.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hang</given-names></name><role specific-use="author">Author</role><aff><institution>Obihiro University of Agriculture and Veterinary Medicine</institution><addr-line><named-content content-type="city">Obihiro</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Shengwei</given-names></name><role specific-use="author">Author</role><aff><institution>Yanbian University</institution><addr-line><named-content content-type="city">Yanji</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Ariefta</surname><given-names>Nanang R</given-names></name><role specific-use="author">Author</role><aff><institution>Obihiro University of Agriculture and Veterinary Medicine</institution><addr-line><named-content content-type="city">Obihiro</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Galon</surname><given-names>Eloiza May S</given-names></name><role specific-use="author">Author</role><aff><institution>Cavite State University</institution><addr-line><named-content content-type="city">Indang</named-content></addr-line><country>Philippines</country></aff></contrib><contrib contrib-type="author"><name><surname>El-Sayed</surname><given-names>Shimaa AES</given-names></name><role specific-use="author">Author</role><aff><institution>Mansoura University</institution><addr-line><named-content content-type="city">Mansoura</named-content></addr-line><country>Egypt</country></aff></contrib><contrib contrib-type="author"><name><surname>Do</surname><given-names>Thom</given-names></name><role specific-use="author">Author</role><aff><institution>Obihiro University of Agriculture and Veterinary Medicine</institution><addr-line><named-content content-type="city">Obihiro</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Lijun</given-names></name><role specific-use="author">Author</role><aff><institution>Yanbian University</institution><addr-line><named-content content-type="city">Yang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Sakaguchi</surname><given-names>Miako</given-names></name><role specific-use="author">Author</role><aff><institution>Nagasaki University</institution><addr-line><named-content content-type="city">Nagasaki</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Asada</surname><given-names>Masahito</given-names></name><role specific-use="author">Author</role><aff><institution>Obihiro University of Agriculture and Veterinary Medicine</institution><addr-line><named-content content-type="city">Obihiro</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Nishikawa</surname><given-names>Yoshifumi</given-names></name><role specific-use="author">Author</role><aff><institution>Obihiro University of Agriculture and Veterinary Medicine</institution><addr-line><named-content content-type="city">Obihiro</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Xin</given-names></name><role specific-use="author">Author</role><aff><institution>Hubei University of Arts and Science</institution><addr-line><named-content content-type="city">Xiangyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Mingming</given-names></name><role specific-use="author">Author</role><aff><institution>Hubei University of Arts and Science</institution><addr-line><named-content content-type="city">Xiangyang</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Xuan</surname><given-names>Xuenan</given-names></name><role specific-use="author">Author</role><aff><institution>Obihiro University of Agriculture and Veterinary Medicine</institution><addr-line><named-content content-type="city">Obihiro</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>In this manuscript, authors have tried to repurpose cipargamin (CIP), a known drug against <italic>Plasmodium</italic> and <italic>Toxoplasma</italic> against <italic>Babesia</italic>. They proved the efficacy of CIP on <italic>Babesia</italic> in nanomolar range. <italic>In silico</italic> analyses revealed the drug resistance mechanism through a single amino acid mutation at amino acid position 921 on the ATP4 gene of <italic>Babesia</italic>. Overall, the conclusions drawn by the authors are well justified by their data. I believe this study opens up a novel therapeutic strategy against babesiosis.</p><p>Strengths:</p><p>Authors have carried out a comprehensive study. All the experiments performed were carried out methodically and logically.</p></disp-quote><p>We appreciate your positive feedback. Your acknowledgment reinforces our commitment to rigor and thoroughness in our research.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Summary:</p><p>The authors aim to establish that cipargamin can be used for the treatment of infection caused by <italic>Babesia</italic> organisms.</p><p>Strengths:</p><p>The study provides strong evidence that cipargamin is effective against various <italic>Babesia</italic> species. In vitro growth assays were used to establish that cipargamin is effective against <italic>Babesia bovis</italic> and <italic>Babesia gibsoni</italic>. Infection of mice with <italic>Babesia microti</italic> demonstrated that cipargamin is as effective as the combination of atovaquone plus azithromycin. Cipargamin protected mice from lethal infection with <italic>Babesia rodhaini</italic>. Mutations that confer resistance to cipargamin were identified in the gene encoding ATP4, a P-type Na+ ATPase that is found in other apicomplexan parasites, thereby validating ATP4 as the target of cipargamin. A 7-day treatment of cipagarmin, when combined with a single dose of tafenoquine, was sufficient to eradicate <italic>Babesia microti</italic> in a mouse model of severe babesiosis caused by lack of adaptive immunity.</p></disp-quote><p>Thank you for the comments and for your time to review our manuscript.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Cipargamin was tested in vivo at a single dose administered daily for 7 days. Despite the prospect of using cipargamin for the treatment of human babesiosis, there was no attempt to identify the lowest dose of cipagarmin that protects mice from <italic>Babesia microti</italic> infection. In the SCID mouse model, cipargamin was tested in combination with tafenoquine but not with atovaquone and/or azithromycin, although the latter combination is often used as first-line therapy for human babesiosis caused by <italic>Babesia microti</italic>.</p></disp-quote><p>Thank you for your insightful comments. We agree that using a single daily dose over 7 days is one of the limitations in the in vivo trial. Our main goals were to demonstrate cipargamin's efficacy and understand its antibabesial agent mechanism. For future work, we plan to conduct dose‐optimization studies to determine the lowest effective dose in vivo. Regarding the drug combination in the SCID mouse model, although atovaquone and/or azithromycin are frequently used as first-line therapies for human babesiosis, resistance to these traditional drugs is emerging. Based on this challenge, we opted to evaluate a combination with tafenoquine as a novel partner, aiming to overcome resistance issues and improve therapeutic outcomes.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>None other than some minor grammatical mistakes.</p></disp-quote><p>We have corrected the grammatical mistakes.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>The revised manuscript is much improved. I have the following comments.</p><p>Comment 1: Atovaquone plus azithromycin is effective against <italic>Babesia microti</italic> (Figure 1C) but not against <italic>Babesia rodhaini</italic> (Figure 1E). It would be valuable to provide a possible explanation.</p></disp-quote><p>Thank you for highlighting this issue. One potential explanation is that <italic>B. microti</italic> and <italic>B. rodhaini</italic> might have intrinsic differences in drug sensitivity and susceptibility. A previous study reported that both species possess a unique linear monomeric mitochondrial genome with a dual flip-flop inversion system, which generates four distinct genome structures (Hikosaka et al., 2012). In addition, previous studies have shown that mitochondria-associated energy production is greater in <italic>B. microti</italic> than in <italic>B. rodhaini</italic> (Shikano et al., 1998). This suggests that <italic>B. microti</italic>, whose metabolism is largely driven by mitochondrial function, may be more susceptible to drugs (like atovaquone) that induce parasite death by disrupting mitochondrial targets such as cytochrome b (Wormser et al., 2010). Moreover, <italic>B. rodhaini</italic> tends to proliferate more rapidly and causes acute infections, which may outpace any drug effects. Further, the rapid proliferation of apicomplexan parasites, as is the case in <italic>Plasmodium</italic> (Salcedo-Sora et al., 2014), <italic>Theileria</italic> (Metheni et al., 2015), and <italic>B. rodhaini</italic> (Rickard, 1970; Shikano et al., 1995), has been ascribed to glycolysis as the primary energy source. This may have contributed to the reduced efficacy of atovaquone and azithromycin in <italic>B. rodhaini</italic>-infected mice in the current study. Nonetheless, we plan to explore these interspecies differences in our future work.</p><disp-quote content-type="editor-comment"><p>Comment 2: The relapse that follows a 7-day treatment with cipargamin is transient in BALB/ mice infected with <italic>Babesia rodhaini</italic> (Figure 1E) but persistent in SCID mice infected with <italic>Babesia microti</italic> (Figure 5C). It would be valuable to provide a possible explanation.</p></disp-quote><p>Thank you for your insightful comment. One possible explanation is the difference in immune status between the two mouse models. BALB/c mice have a fully functional immune system that can likely clear residual parasites following a transient relapse after cipargamin treatment. In contrast, SCID mice lack an adaptive immune response, which might allow residual <italic>B. microti</italic> parasites to persist and cause a sustained relapse. Additionally, intrinsic differences between <italic>B. rodhaini</italic> and <italic>B. microti</italic>, such as growth rate or drug susceptibility, could also play a role. We plan to explore these factors in future studies.</p><disp-quote content-type="editor-comment"><p>Comment 3: The effect of cipargamin on parasite pH is the greatest when assessed 4 to 8 min after exposure is initiated (Figure 3E). Yet, resistance of parasites that carry a mutation in ATP4, the target of cipargamin, was assessed 20 min after cipargamin addition. At this time point, cipargamin has very little effect (Figure 3E). Accordingly, data reported in Figure 3G are of limited value.</p></disp-quote><p>Thank you for your comment. The initial pH increase we see around 4 to 8 minutes likely reflects the rapid inhibition of ATP4-mediated Na⁺/H⁺ exchange by cipargamin, which quickly alkalinizes the cell. However, after the initial increase, compensatory processes, such as proton influx or metabolic acid production, gradually restored the pH, resulting in a later decline. Although assessing the pH level at 20 minutes may have recorded less dramatic changes, it still allowed us to compare the sustained differences between wild-type and mutant strains. We agree that including earlier time points for the mutants might provide further insight and we will consider this in our future work.</p><disp-quote content-type="editor-comment"><p>Comment 4: In Figure 3H, please report the lack of statistical significance between wild-type parasites and parasites that carry the mutation L921V.</p></disp-quote><p>In Figure 3H, the ATPase activity in erythrocytes infected with wild-type parasites (6.31 ± 1.20 nmol Pi/mg protein/min) is higher than that of the L921V mutation (5.11 ± 0.50 nmol Pi/mg protein/min), but the difference is not statistically significant (<italic>P</italic> = 0.095), so no asterisk was added.</p><disp-quote content-type="editor-comment"><p>Comment 5: Tafenoquine was administered as a single 20 mg/kg dose. Please specify whether this dose is for tafenoquine succinate or tafenoquine base.</p></disp-quote><p>Thank you for raising this point. In our study, the single 20 mg/kg dose refers to tafenoquine succinate. We have clarified this detail in the revised manuscript (Line 40).</p><disp-quote content-type="editor-comment"><p>Comment 6: A single dose of 20 mg/kg tafenoquine succinate was first tested in the SCID mouse model of severe babesiosis by Mordue et al (JID 2019), not by Liu et al. (JID 2024). Please amend discussion accordingly (line 311). As correctly stated in the discussion, the single 20 mg/kg dose was not sufficient to prevent relapse of <italic>Babesia microti</italic> in the study by Mordue et al. Please provide a possible explanation for why no parasitemia was detected for 90 days in your SCID model (Figure 5C).</p></disp-quote><p>Thank you for your comment. We have modified the suggested citation (Line 309). As noted by Mordue et al. (JID 2019), a single 20 mg/kg dose of tafenoquine succinate was insufficient to prevent relapse in their SCID mouse model using <italic>B. microti</italic> (ATCC 30221 Gray strain). In our study, however, no parasitemia was detected for 90 days (Figure 5C) using the <italic>B. microti</italic> Peabody mjr strain (ATCC PRA-99). Differences in the parasite strain and the timing of treatment relative to infection may have contributed to the extended suppression of parasitemia observed in our study. We plan to explore these aspects in future work.</p><disp-quote content-type="editor-comment"><p>Comment 7: Real-time PCR was used to confirm eradication of <italic>Babesia microti</italic> infection (Figure 5D). Please specify the blood volume from which genomic DNA was extracted for each mouse. Please specify the amount of genomic DNA (i.e., not the volume) used in each reaction. Please explain how/why the cut-off was set at 35 cycles. What were the Ct values when blood was obtained from uninfected mice? For infected mice treated with cipargamin plus tafenoquine, there was no amplification. Was each reaction subjected to a maximum of 40 cycles (as suggested by Figure 5D)?</p></disp-quote><p>In our qPCR assay, genomic DNA was extracted from 200 µL of blood per mouse (Line 458). In each reaction, we used 100 ng of genomic DNA (Line 464), and the thermocycling conditions were set at 40 cycles. We set the cut-off at 35 cycles based on our optimization experiments: samples with Ct values ≤ 35 consistently indicated the presence of parasite DNA, while samples without parasite DNA (distilled water and DNA from uninfected mice) had CT values &gt; 35 cycles or undetectable. Although each reaction was run for 40 cycles, for our analysis, we defined samples as negative if no signal was observed beyond cycle 35. In mice treated with cipargamin plus tafenoquine, no signal was detected until 40 cycles, indicating the absence of parasite DNA in the samples.</p><disp-quote content-type="editor-comment"><p>Comment 8: Persistence of parasite DNA in blood of tafenoquine treated mice highlights the limitation of PCR to assess persistence of infection. That is, PCR cannot distinguish between viable parasites and non-viable (or dead) parasites. An adoptive transfer of blood to immunocompromised mice can help determine whether persistence of DNA is due to persistence of viable parasites. Because the experiment was carried out in SCID mice, no adoptive transfer is needed. Few parasites are required for a successful infection of immunocompromised mice (SCID mice included). Given that parasitemia never rose following treatment of SCID mice with a single dose of tafenoquine, it is highly likely that parasite DNA detected on day 90 post-infection in these tafenoquine treated mice came from persistent non-viable/dead parasites.</p></disp-quote><p>We appreciate your comment and acknowledge that the use of PCR has limitations in differentiating between live and dead parasites. It is possible that the residual DNA may represent a small population of dormant parasites that are not actively replicating and thus remain below the detection threshold of parasitemia. Even in highly immunocompromised SCID mice, such dormant parasites might persist without causing overt infection under our experimental conditions. An adoptive transfer experiment in SCID mice, although not strictly necessary, could validate whether the detection of low levels of DNA comes from viable parasites capable of reactivating under different circumstances. Future studies using more sensitive viability assays or adoptive transfer approaches could provide further insights into this possibility.</p></body></sub-article></article>